e roche finance report fhoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom finance brief key results sales cer growth core operating profit margin sales pharmaceuticals diagnostics group change sales mchf mchf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant currencies average rates year ended december concept previously labelled local currencies group core results core eps earnings per share exclude noncore items global restructuring charges amortisation impairment intangible assets allows transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given therefinance brief roche roche group posted solid overall results challenging market core operating profit grew faster sales core earnings per share increased constant exchange rates cer appreciation swiss franc major currencies significant impact results expressed swiss francs however underlying currency exposure mitigated large majority cost base located outside switzerland sales group sales increased slightly cer billion swiss francs reported exchange rates excluding tamiflu group sales grew cer pharmaceutical sales growth excluding tamiflu cer strong growth key oncology products lucentis ophthalmology actemraroactemra rheumatoid arthritis largely offset impacts us healthcare reforms european austerity measures price cuts japan lower avastin sales us western europe diagnostics sales grew cer significantly ahead market professional diagnostics tissue diagnostics major contributors operating results core operating profit increased cer billion swiss francs reported exchange rates cost savings operational excellence programme initiated offset substantially lower profit contribution avastin tamiflu well impacts healthcare reforms price pressure patent expiry research development expenditure declined cer billion swiss francs core basis primarily driven project prioritisation savings operational excellence rd costs group sales ifrs operating results include restructuring charges operational excellence programme billion swiss francs nonoperating results core net financial expenses decreased million swiss francs primarily due lower interest expenses resulting continued repayment debt taken finance genentech transaction net income ifrs net income increased cer billion swiss francs reported exchange rates primarily driven strong operating result lower restructuring charges lower interest expenses lower tax rate core earnings per share increased constant currencies reported exchange rates cash flows operating free cash flow billion swiss francs cer free cash flow billion swiss francs cer repayment debt ahead schedule notes bonds issued finance genentech transaction repaid end financial position net working capital increased reflecting higher levels trade receivables within public sector customers certain southern european countries net debt position improved billion swiss francs billion swiss francs credit ratings position strong moodys upgraded second half standard poors aa shareholder return dividends proposed increase represent th consecutive year dividend growth result increased payout ratio subject agm approval total shareholder return tsr increased representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements summary significant accounting policies ccounts receivable perating segment information current assets c hugai arketable securities financial income financing costs cash cash equivalents ncome taxes ccounts payable b usiness combinations accrued current liabilities global restructuring plans derivative financial instruments e mployee benefits provisions contingent liabilities pensions postemployment noncurrent liabilities benefits ebt employee stock options equity equity attributable roche shareholders compensation plans earnings per share nonvoting equity property plant equipment security g oodwill n oncontrolling interests ntangible assets statement cash flows ssociates r isk management financial longterm assets r elated parties nventories subsidiaries associates report roche management internal control financial reporting report statutory auditor consolidated financial statements report independent auditor internal control financial reporting multiyear overview supplementary information roche securities roche hol ding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditor financial statements financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups net income increased constant exchange rates driven solid operating performance pharmaceuticals diagnostics businesses costs restructuring less financing costs tax rate also lower cost savings operational excellence programme initiated offset substantially lower profit contribution reduced sales tamiflu avastin well impacts healthcare reforms price pressure patent expiry strengthening swiss franc major currencies average yeartodate basis significant negative impact results expressed swiss francs however underlying currency translation exposure arising nonswiss franc revenues mitigated majority groups cost base located outside switzerland groups net income increased constant exchange rates increased translated consolidation swiss francs core eps excludes noncore items global restructuring charges amortisation impairment intangible assets increased constant exchange rates decrease translated swiss francs roche group financial review roche finance report income statement change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests diluted eps chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps chf roche finance report roche group financial reviewsales sales increased slightly constant currencies swiss francs us dollars billion swiss francs excluding tamiflu sales increased constant currencies pharmaceuticals division represented group sales diagnostics division contributed sales pharmaceuticals division stable constant currencies billion swiss francs excluding tamiflu increase demand oncology drugs herceptin mabtherarituxan xeloda tarceva continued grow strongly additional major growth drivers lucentis ophthalmology actemraroactemra rheumatoid arthritis mircera renal anemia positive factors mostly offset expected declines sales tamiflu avastin patent expiry effects neorecormonepogin bonvivaboniva cellcept continuing negative impacts us healthcare reforms european austerity measures price cuts japan diagnostics division sales billion swiss francs growing constant currencies swiss francs us dollars thereby strengthening leading market position major growth areas professional diagnostics tissue diagnostics divisional operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase core operating results core basis groups operating profit increased constant exchange rates decreased swiss francs sales increased cer core operating profit margin divisions increased increase profitability driven operational excellence programme resource prioritisation particularly marketing distribution research development operational excellence programme led decline marketing distribution expenses research development costs constant currencies strong swiss franc negative effect margin developments percentage points group level percentage point pharmaceutical division percentage point diagnostics division roche group financial review roche finance report pharmaceuticals division increased core operating profit constant currencies driven growth underlying business resource prioritisation operational excellence cost savings efficiency improvements general administration costs offset million swiss francs expenses new branded pharmaceutical product fee us part us healthcare reforms core operating profit growth diagnostics division constant currencies mainly resulting sales growth various productivity improvement programmes increase general administration costs corporate due shift certain finance functions pharmaceuticals division corporate operational excellence november group announced details operational excellence programme costs recognised billion swiss francs mainly relate site closure disposal costs pharmaceutical business site closure disposal costs totalled million swiss francs primarily due divestments sites palo alto california boulder colorado madison wisconsin kulmbach germany first half group announced divest chemical production facility florence south carolina given unfavourable market chemical production assets groups expected future capacity requirements small molecules pharmaceuticals division accounts million swiss francs costs million swiss francs relate diagnostics division east japan earthquake earthquake march damaged chugai production plant utsunomiya production temporarily halted fully resumed end august chugais contract manufacturers also affected earthquake result product shipment control lasted end october chugais promotional activities japan affected events cancelled sales employees diverted ensure continued product supply information flow customers factors certain negative impact chugais sales profits second half total costs incurred writeoffs property plant equipment inventories chugai million swiss francs net amounts received insurance earthquake also resulted temporary interruptions supply instruments hitachi key supplier roche professional diagnostics business treasury taxation financial income billion swiss francs increase constant exchange rates mainly due foreign currency devaluation effects venezuela financing costs billion swiss francs decrease billion swiss francs interest costs lower cer debt repaid tax expenses increased billion swiss francs however groups effective core tax rate decreased compared mainly due lower tax rate basel switzerland relatively lower percentage profit contribution highertax jurisdictions net income earnings per share net income increased constant exchange rates driven solid operating performance lower financing costs lower tax rate overall lower noncore items global restructuring charges genentech integration lower charges operational excellence initiative core basis net income higher increase diluted eps cer due increase net income described core eps excludes noncore items global restructuring charges amortisation impairment intangible assets increased constant exchange rates decreased swiss francs supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results roche finance report roche group financial reviewfinancial position change change mchf mchf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets first half swiss franc strengthened many currencies following intervention swiss central bank trend reversed second half overall currency translation effects largely netted balance sheet carrying values consolidated swiss francs pharmaceuticals division net working capital decreased constant currencies despite increased trade receivables within public sector customers southern european countries particularly spain portugal continued sales growth china longterm net operating assets decreased constant currencies utilisation provisions created operational excellence restructuring programme offset lower property plant equipment following various site disposals diagnostics increase net working capital constant currencies driven buildups trade receivable certain southern european countries increased inventory levels due product launches buildup hitachi sourced instruments earthquake japan longterm net operating assets constant currencies increased creation provisions partially offset higher levels property plant equipment improvement net debt position mainly due free cash flow billion swiss francs described pensions increase net pension liability reflects falling interest rates leading discounted defined benefit obligation higher free cash flow change change mchf mchf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid dividends paid free cash flow groups operating free cash flow remained strongly positive billion swiss francs increase constant currencies swiss francs driven strong operating results partly offset increases net working capital proceeds site divestments lower capital expenditure also contributed growth operating free cash flow free cash flow decreased billion swiss francs billion swiss francs primarily due lower free cash flow swiss franc terms higher dividend payments roche group financial review roche finance report pharmaceuticals division operating results pharmaceuticals division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps roche finance report roche group financial reviewsales overview pharmaceuticals division sales therapeutic area change sales sales therapeutic area mchf mchf cer oncology inflammationautoimmunetransplantation virology metabolismbone ophthalmology respiratory diseases renal anemia cardiovascular diseases central nervous system infectious diseases therapeutic areas total sales pharmaceuticals division sales stable constant currencies growth key products offsetting negative impacts healthcare reforms austerity measures pricing pressures expected decreases sales certain major medicines excluding tamiflu sales growth pharmaceuticals division constant currencies primarily driven five products herceptin mabtherarituxan lucentis actemraroactemra mircera products represent portfolio together generated billion swiss francs additional sales growth partly offset lower sales tamiflu avastin neorecormonepogin bonvivaboniva cellcept us healthcare reforms european austerity measures base effect japanese biennial price cuts implemented april combined incremental negative impact million swiss francs compared equivalent percentage points divisional sales growth oncology continued account majority divisions sales continued growth herceptin mabthera rituxan offsetting expected decline avastin sales virology sales tamiflu continued decrease substantially overall pegasys sales declined year began recover second half following us launches new hepatitis c medicines used combination pegasys sales inflammationautoimmunetransplantation increased constant currencies due strong uptake actemraroactemra growth mabtherarituxan rheumatoid arthritis compensating negative impact continued generic erosion cellcept roche group financial review roche finance report product sales pharmaceuticals division sales change sales sales mchf mchf cer oncology avastin herceptin mabtherarituxan xeloda tarceva neutrogin neorecormonepogin others total oncology inflammationautoimmunetransplantation cellcept mabtherarituxan actemraroactemra others total inflammationautoimmune transplantation virology pegasys valcytecymevene tamiflu copegus others total virology metabolismbone bonvivaboniva nutropin xenical evista others total metabolismbone ophthalmology lucentis total ophthalmology respiratory diseases xolair pulmozyme total respiratory diseases renal anemia neorecormonepogin mircera total renal anemia roche finance report roche group financial reviewpharmaceuticals division sales continued change sales sales mchf mchf cer cardiovascular diseases activasetnkase others total cardiovascular diseases central nervous system madopar rivotril others total central nervous system infectious diseases rocephin others total infectious diseases therapeutic areas total sales total mabtherarituxan sales million swiss francs million swiss francs split oncology inflammationautoimmune transplantation franchises total neorecormonepogin sales million swiss francs million swiss francs split renal anemia oncology franchises mabtherarituxan change sales sales mchf mchf cer united states western europe japan international total sales mabtherarituxan nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra ancaassociated vasculitis sustained growth oncology segment driven continued strong uptake new firstline maintenance indication follicular lymphoma type nhl europe us uptake cll sales growth international region including key emerging markets china brazil mainly due continued uptake nhl indications sales ra segment billion swiss francs increase constant currencies growth segment came increased use patients inadequate response treatment tumour necrosis factor inhibitors also shortened repeat treatment intervals avastin change sales sales mchf mchf cer united states western europe japan international total sales roche group financial review roche finance report avastin advanced colorectal breast lung kidney ovarian cancer relapsed glioblastoma type brain tumour significant decline overall sales mainly due regulatory reimbursement uncertainty us beginning regarding use avastin metastatic breast cancer led lower sales us throughout also affected uptake breast cancer certain european latin american markets us market share indications remained stable lower sales europe due primarily government austerity measures price cuts along lower use breast cancer market penetration colorectal cancer remained stable despite increasing competition use medicine lung cancer grew slightly number eu countries approval eu december avastin frontline treatment newly diagnosed advanced ovarian cancer expected positive impact sales europe onwards growth international region reflects strong uptake avastin colorectal lung cancer indications led latin america asiapacific particularly china following launch colorectal cancer october growth japan driven continued good uptake nonsmall cell lung cancer new metastatic breast cancer indication approved japan september also expected contribute future sales november us food drug administration issued final decision revoking approval avastin treatment metastatic breast cancer followed recommendation july fda expert panel agencys initial notice revocation december appeal roche genentech removal indication fda decision affect medicines approved indications us elsewhere avastin currently approved markets worldwide including eu recently japan breast cancer herceptin change sales sales mchf mchf cer united states western europe japan international total sales herceptin herpositive breast cancer herpositive metastatic advanced stomach cancer global sales growth driven expanded access developing countries together increased improved testing continued uptake herpositive stomach cancer international region grew demand especially strong latin america asiapacific region higher sales us primarily reflect good adoption medicine stomach cancer increase western europe due mainly uptake stomach cancer higher penetration elderly population breast cancer well enhanced penetration quality testing modest growth japan reflected reduction promotional activities following earthquake march main growth contribution came sales herpositive breast cancer segment herceptin maintained high market share also initial uptake new stomach cancer indication approved japanese authorities march lucentis change sales sales mchf mchf cer united states total sales roche finance report roche group financial reviewlucentis wet agerelated macular degeneration amd macular edema following retinal vein occlusion rvo sales us grew us dollar terms billion swiss francs main factors growth amd market new rvo indication april oneyear results comparisons agerelated macular degeneration treatments trial catt published compared lucentis offlabel avastin patients wet amd limited impact us sales growth total lucentis patient share wet amd segment remained stable us third fourth quarters due part reports safety concerns regarding unapproved intravitreal use avastin wet amd lucentis marketed outside united states novartis pegasys change sales sales mchf mchf cer united states western europe japan international total sales pegasys hepatitis b c overall sales decline partly offset renewed sales growth second half increase compared period recovery followed launches mid two new directacting hepatitis c medicines us mercks victrelis vertexs incivek new medicines designed given pegylated interferon ribavirin regimen known triple combination therapy leading pegylated interferon medication pegasys well positioned foundation triple combination therapy europe elsewhere patients doctors delaying start hepatitis c treatment anticipation availability reimbursement triple combination therapy expected increase treatment deferrals resulted contraction hepatitis c segment mature markets recent years pegasys continued expand leading market share us key eu countries japan roche merck co established strategic nonexclusive agreements improve treatment diagnosis awareness chronic hepatitis c agreements roche genentech include victrelis boceprevir part promotion healthcare professionals use pegasys triple combination regimen pegasys prefilled penproclick autoinjector makes administering pegasys even simpler approved eu us rolled xeloda change sales sales mchf mchf cer united states western europe japan international total sales xeloda colorectal stomach breast cancer sales increased constant currencies billion swiss francs growth driven primarily strong demand us china brazil increased us sales partly due shortages certain alternative cancer medicines sales western europe impacted governmentmandated price cuts key markets decline japan primarily due effects east japan earthquake roche group financial review roche finance report tarceva change sales sales mchf mchf cer united states western europe japan international total sales tarceva advanced nonsmall cell lung pancreatic cancer overall sales increase due primarily strong growth international region especially china brazil south korea driven uptake secondline treatment nonsmall cell lung cancer nsclc growth us reflects continued growth nsclc firstline maintenance indication growth secondline nsclc segment highly competitive japanese market increase sales primarily due uptake tarceva secondline nsclc oncologists increasing confidence benefits treatment medication pricing pressure competitive challenges negatively affected sales western europe offsetting positive impact volume gains initial launches new firstline epidermal growth factor receptor egfr mutationpositive metastatic nsclc indication cellcept change sales sales mchf mchf cer united states western europe japan international total sales cellcept prevention solid organ transplant rejection sales declined sharply due continued generic erosion us western europe following patent expiry respectively sales many countries international region also negatively affected price pressure increased use generics continued growth japan reflects position cellcept standard care approved indications neorecormonepogin change sales sales mchf mchf cer united states western europe japan international total sales neorecormonepogin anemiarenal anemia highly competitive market groups overall market share anemia franchise slightly year combined sales roches neorecormon chugais epogin epoetin beta declined constant currencies western europe international regions sales lower due increasing biosimilar competition market decline cancerrelated anemia segment competitive pressure lower reimbursement price resulted reduced sales epogin japan roche finance report roche group financial reviewthe sustained decline sales neorecormon epogin partly offset strong growth sales longeracting erythropoiesisstimulating agent mircera methoxy polyethylene glycolepoetin beta rose constant exchange rates million swiss francs much growth due increasing number patients switching starting treatment mircera place neorecormonepogin strongest contributions higher mircera sales came japan product launched chugai july international region accounts total mircera sales bonvivaboniva change sales sales mchf mchf cer united states western europe japan international total sales bonvivaboniva osteoporosis sales western europe lower due entry generics market together pricing reimbursement issues decrease us reflects falling market demand reserve adjustments strong growth asiapacific constant currencies led south korea offset lower sales rest international region notably eastern european countries brazil actemraroactemra change sales sales mchf mchf cer united states western europe japan international total sales actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis sales continued grow strongly approved indications regions sales increased particularly us actemra continues gain market share also western europe japan latin america marketing reimbursement approvals additional countries continue expand patient access actemraroactemra sustained growth us elsewhere due uptake later lines therapy depending approved indication sales japan grew strongly due increasing use actemra firstline later lines therapy supported recognition high remission rates achieved medicine ra tamiflu change sales sales mchf mchf cer united states western europe japan international total sales roche group financial review roche finance report tamiflu influenza b following unprecedented demand due influenza hn pandemic sales continued decline strongly reflecting baseline effect also moderate influenza seasons hemispheres significantly higher sales governments particularly japan international region notably brazil south korea taiwan mexico limited sales governments primarily driven replacement expiring pandemic stockpiles zelboraf change sales sales mchf mchf cer united states western europe japan international total sales zelboraf braf vmutated metastatic melanoma us food drug administration approved zelboraf august enabling genentech launch new targeted cancer medicine united states less four months marketing application filed fda simultaneously approved roche diagnostics cobas braf v mutation test companion diagnostic used identify patients treatment zelboraf appropriate initial sales zelboraf strong broad payer coverage already achieved marketing approval also obtained switzerland brazil fourth quarter december european medicines agencys committee medicinal products human use chmp unanimously recommended zelboraf granted full eu marketing approval marketing applications filed number countries including australia new zealand rates malignant melanoma high pharmaceuticals division sales region change sales sales region mchf mchf cer united states western europe japan international cemai latin america asiapacific regions total sales central eastern europe middle east africa central asia indian subcontinent united states sales grew us dollar terms growth driven lucentis mabtherarituxan actemra herceptin offsetting decline us avastin sales addition impact us healthcare reforms led reduction sales approximately million us dollars million swiss francs increased rebates affecting major products compared million us dollars million swiss francs western europe sales decreased constant currencies despite growth oncology products mabthera rituxan herceptin uptake actemraroactemra decline due lower avastin sales continuing impact generic erosion cellcept bonvivaboniva sales lower sales neorecormon highly competitive renal anemia market addition estimated million euros million swiss francs negative impact european austerity measures compared million euros million swiss francs roche finance report roche group financial reviewjapan decrease sales japanese yen terms due primarily direct indirect effects earthquake march decline government purchases tamiflu emergency relief efforts rapid implementation chugai recovery programme ensure product supplies restore production took priority marketing activities normal operations resumed towards end ensure uninterrupted supplies medicines patients shipment controls introduced number key products immediately following earthquake cases controls maintained well fourth quarter promotional activities reduced accordingly addition first half still residual effect mandatory twoyearly pharmaceutical price cuts implemented april growth avastin launch mircera higher actemra sales offset lower sales epogin pegasys kytril international asiapacific showed particularly strong growth led oncology franchise top selling products herceptin mabtherarituxan avastin china main driver overall sales growth growth latin america also mainly due oncology products especially herceptin mabtherarituxan avastin mexico negative impact biosimilar competition actemraroactemra sales also continued grow latin america increasing underlying sales growth brazil south korea offset significantly lower tamiflu sales excluding tamiflu growth respectively excluding tamiflu total sales e key emerging markets grew sales excluding tamiflu cemai subregion declined due political developments north africa middle east well price pressure eastern european markets pharmaceuticals division sales e leading emerging markets change change cer cer excluding sales sales country mchf mchf total tamiflu brazil china india mexico russia south korea turkey total sales operating results pharmaceuticals division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalty income increased constant exchange rates mainly result higher lucentis royalties increase constant currencies outlicensing agreements driven milestone income marcadia compounds lucentis also higher income profit sharing agreements income disposal products relatively stable roche group financial review roche finance report pharmaceuticals division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements restructuring expenses impairment property plant equipment cost sales core basis global restructuring operational excellence amortisation intangible assets impairment intangible assets east japan earthquake total ifrs basis cost sales core basis decreased constant currencies mainly result lower royalty expenses percentage sales cost sales increased slightly increase manufacturing cost goods sold period costs mainly due product mix effects startup activities product launches inventory writeoffs second half royalty expenses lower mainly arising expiring royalty obligations herceptin major eu countries beginning late well lower sales tamiflu contractual changes us sales bonvivaboniva partly offset back royalty expenses million swiss francs related rituxan arbitration see note consolidated financial statements expenses collaboration profitsharing agreements decreased part due estimated million swiss francs would recoverable respect rituxan arbitration mentioned site closure disposal costs manufacturing logistics area million swiss francs recorded part operational excellence programme addition due east japan earthquake million swiss francs costs reported impairments repairs maintenance plants writeoffs raw materials intermediates chugai pharmaceuticals division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring operational excellence east japan earthquake total ifrs basis core costs decreased due tight cost management savings operational excellence programme percentage sales costs decreased percentage points sales marketing efforts focused oncology portfolio rollout additional approved indications avastin mabtherarituxan herceptin continued rollouts actemraroactemra rheumatoid arthritis costs also incurred continued support pegasys xeloda tarceva significant bad debt provision expenses totalling million swiss francs incurred particular southern european countries noncore costs million swiss francs recorded part operational excellence programme related employee termination costs roche finance report roche group financial reviewpharmaceuticals division research development change mchf mchf cer research development core basis global restructuring operational excellence amortisation intangible assets impairment intangible assets total ifrs basis core costs lower due resource prioritisation savings operational excellence programme research development costs percentage sales compared oncology remained main focus area higher investments central nervous system virology offset lower lifecycle investments metabolism inflammation operational excellence costs million swiss francs relate primarily site disposals property plant equipment impairments impairment charge intangible assets relates assets acquired alliance transactions acquisitions majority large impairment arose project terminations operational excellence programme addition pharmaceuticals division spent million swiss francs inlicensed acquired pipeline compounds technologies capitalised intangible assets pharmaceuticals division general administration change mchf mchf cer administration restructuring expenses gains losses disposal property plant equipment business taxes general items general administration core basis global restructuring operational excellence global restructuring genentech transaction alliances business combinations legal environmental settlements east japan earthquake total ifrs basis core costs increased mainly due new branded pharmaceutical product fee us cost impact million swiss francs excluding fee constant currency core costs decreased driven lower administration costs due savings organisational shift certain finance functions corporate noncore costs general administration area included costs million swiss francs relating operational excellence consists mainly site disposal costs us sites boulder colorado madison wisconsin site kulmbach germany costs partly offset gain disposal site palo alto california additionally various itrelated expenses operational excellence alliances business combinations include million swiss francs related reversal provisions contingent consideration arrangements business combinations roche group financial review roche finance report financial position pharmaceuticals division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventories payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts first half swiss franc strengthened many currencies following intervention swiss central bank trend reversed second half result end us dollar exchange rate start year euro slightly weaker swiss franc japanese yen strengthened swiss franc yearonyear swiss franc strengthened currencies brazilian real turkish lira overall effects almost completely netted total net operating assets pharmaceuticals division consolidated swiss francs net working capital decrease constant currencies mainly due decreases inventories receivables prepaid expenses balance sheet value inventories decreased mainly due inventory writeoffs made second half certain buildup key growth markets china asiapacific latin america regions trade receivables increased main factors increases public sector receivables southern european countries particularly spain portugal also continued growth business china increases offset decrease million swiss francs following settlement public sector trade receivables government bonds greece payables increased slightly accrued royalty liabilities increasing longterm net operating assets property plant equipment decreased mainly due various site divestments operational excellence programme time additions completion new manufacturing facilities expansion technical research development facilities basel switzerland penzberg germany goodwill intangibles increased mainly due acquisition anadys pharmaceuticals decrease provisions mainly related settlement obligations operational excellence programme roche finance report roche group financial reviewfree cash flow pharmaceuticals division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments increase decrease net working capital receivables inventories payables total increase decrease net working capital investments property plant equipment investments intangible assets total investments operating free cash flow sales detailed breakdown provided pharmaceuticals division generated strong operating free cash flow billion swiss francs increase constant currencies compared driven strong operating profit performance lower capital expenditure offset increases working capital trade receivables increased partly result continued sales growth china another factor significant increase trade receivables within public sector customers southern european countries particularly spain portugal measures taken improve collections countries including intense communication customers negotiations payment plans charging interest late payments legal action cash flow perspective cash invested inventories increased due growth key growth markets asiapacific latin america especially china payables increased due increases accrued royalty liabilities operating profit cash adjustments decreased mainly due significant cash outflows utilisation operational excellence programme provisions lower depreciation amortisation impairments partially offset cash received disposals roche group financial review roche finance report diagnostics division operating results diagnostics division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales diagnostics business continued increase sales significantly vitro diagnostics ivd global market growth constant currencies professional diagnostics sales growth leveraged immunodiagnostics tissue diagnostics sales growth driven sales advanced staining market main growth contributors business areas growing around twice rate respective markets diabetes care sales increased million swiss francs increase constant currencies sales molecular diagnostics totalled million swiss francs increase driven virology segment applied science sales decreased due yearonyear decline hn influenza virus testing increasing competition sequencing slowdown research funding roche finance report roche group financial reviewdiagnostics division sales business area change sales sales business area mchf mchf cer professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics total sales professional diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales professional diagnostics sales grew almost double rate global market especially strong growth emerging markets early roche professional diagnostics took leading position market includes ivd products clinical laboratories hospitalambulatory pointofcare testing key drivers growth growth immunoassays business roche broadest menu offering industry tests growth clinical chemistry business instrument placements whole despite temporary disruptions supply instruments manufacturing partner hitachi high technologies due east japan earthquake growth coagulation monitoring business ongoing conversion patients selftesting led increase professional diagnostics leading market share sector despite introduction new anticoagulant therapies market emea europe middle east africa north america regions business maintained growth market levels particularly increased market penetration north america international region continued abovemarket growth led asiapacific latin america investments china contributed growth strengthened roche professional diagnostics market leadership position country year business launched seven new immunoassays cobas c clinical chemistry module amongst new immunoassays hbsag quant assay determines hepatitis b viral load pegasys therapy immunoassay helps detect early ovarian cancer vitamin total measurement vitamins business completed acquisition pvt leader laboratory automation workflow early acquired verum diagnostica leading company platelet function testing roche group financial review roche finance report diabetes care change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales diabetes care sales increased slightly environment impacted price pressure slow volume growth increasing regulatory requirements particularly us growth rest world regions partly offset reduced sales north america despite challenging market diabetes care remains leader global blood glucose bg monitoring holding close one third global market main growth drivers new generation accuchek bg monitoring systems accuchek combo combined insulin pump bg meter good sales development products emea rest world regions helped strengthen roche diabetes cares market position especially strong growth asiapacific latin america us decline sales mainly due postponed launch latest additions new accuchek portfolio fdas clearance new maltoseindependent chemistry accuchek aviva plus test strip third quarter marked first step bringing new portfolio us expected drive future growth key market late roche diabetes care started launching next generation stripfree bg meter accuchek mobile australia netherlands insulin delivery segment insulin pumps sales grew driven mainly increased number patients accuchek combo whereas sales infusion sets negatively impacted voluntary recall accu chek flexlink plus molecular diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales molecular diagnostics growth sales due strong performance north america rest world regions notably united states china roche molecular diagnostics retains leadership position global molecular diagnostics market close one third global market large expanding test menu business main sales growth came hiv hbv viral load tests blood screening business grew emea region spite pricing pressures virology blood screening segments overall business remained stable majority share market fdas approval human papillomavirus hpv test april business entered largest single fastest growing molecular testing market hpv test experienced positive uptake eu previously launched tender karolinska university hospital sweden first large pilot project eu hpv primary screening us partnerships contracts signed major laboratories physician sales force started expand hpv business business area continued build novel oncology portfolio launch tests detecting cancerrelated mutations braf melanoma egfr lung cancer kras colorectal cancer genes complementing roches portfolio companion diagnostics cobas braf test seen strong market uptake available europe americas asiapacific developments personalised healthcare came partnerships large pharmaceutical companies including merck clovis well continued internal roche projects future assays detection biomarkers roche finance report roche group financial reviewapplied science change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales applied science sales decline driven emea north america regions also japan due slowdown research funding increasing competition gene sequencing yearonyear effect large orders hn influenza testing early effect especially marked asiapacific region sales decline excluding effect sales asiapacific increased custom biotech biochemicals business accounts approximately applied sciences revenues continued healthy growth increase sales business supplies various products healthcare industry including specialty biochemicals new bioprocess analyser instrument placements declined genomics pcr analysis businesses leading reduction sales respectively despite products continued gain market share generate growth include test kits gs junior benchtop system gene sequencing test kits magna pure dna sample preparation seqcap microarrays targeted sequencing major launch year lightcycler nano small affordable instrument automised pcr analysis tissue diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales grew substantially ahead market regions reinforcing business leadership position tissuebased cancer diagnostics emea japan sales grew double market rate reflecting intensified uptake roche tissue diagnostics automated solutions novel advanced staining tests regions growth driven increasing instrument placements well increasing sales immunohistochemistry ihc situ hybridisation ish assays used detect proteins genes tissue samples including new antibodies ihc testing business industryleading test menu includes readytouse antibody tests newly launched optiview system improves sensitivity visualisation ihc assays enabling pathologists improve detection biomarkers tissue samples june roche tissue diagnostics launched dual ish test us supporting personalised breast cancer treatment test seen rapid uptake worldwide achieving leadership position eu markets combined b ihc test companion algorithm b analytical imaging software business offers complete diagnostic workflow laboratories business completed acquisition mtm laboratories leader cervical cancer vitro diagnostics roche group financial review roche finance report diagnostics division sales region change sales sales region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sales sales continued grow regions asiapacific region achieved strong growth led china growing south korea growing growth driven mainly professional diagnostics partly offset lower applied science sales due nonrecurrence orders first half related hn influenza tests despite pricing challenges emea europe middle east africa north america sales regions grew respectively driven professional diagnostics north america divisions market share continued grow vitro diagnostics business strong sales area offsetting decline diabetes care sales following postponed launches us japan good performances professional diagnostics tissue diagnostics partly offset lower sales applied science resulting total sales growth diagnostics division sales e leading emerging markets change sales sales country mchf mchf cer brazil china india mexico russia south korea turkey total sales sales growth e emerging markets led china contributions russia south korea strong growth china driven demographic change healthcare reform foresees investment billion us dollars primary healthcare next three years provides national insurance plan population growth china particularly strong professional diagnostics molecular diagnostics businesses significant growth russia achieved winning major tenders mainly professional diagnostics molecular diagnostics related russian healthcare modernisation programme operating results diagnostics division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis decrease royalty operating income due fall royalty income result patent expiration us taqman pcr patents molecular diagnostics higher royalty expense royalty income due payments patent owners molecular diagnostics idaho pcr contracts professional diagnostics hcv bioprocess patents roche finance report roche group financial reviewdiagnostics division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring operational excellence amortisation product intangibles impairment product intangibles total ifrs basis growth core costs lower sales growth resulting lower costofsales ratio previous cost reduction initiatives centralisation logistics services harmonisation technical services practices renegotiations supplier contracts continued positive impact partly compensated higher depreciation installation costs technical service costs continued investments expand market share meter placements increase installed instrument base decrease royalty expenses million swiss francs due patent expirations certain inlicensed intellectual property part operational excellence programme costs million swiss francs incurred mainly relating employeerelated costs graz austria rotkreuz burgdorf switzerland decrease amortisation constant currencies mainly due certain assets becoming fully amortised partly offset amortisation recently acquired intangible assets medingo mtm laboratories second half impairment million swiss francs booked intangibles sequencing array businesses diagnostics division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring operational excellence amortisation intangible assets total ifrs basis marketing distribution costs increased reflecting higher costs molecular diagnostics notably microbiology area launch cobas hpv dna test professional diagnostics immunoassay clinical chemistry segments remain highest contributors particular due increased distribution costs following east japan earthquake led change shipping air freight increase also comes higher marketing support advanced staining assay portfolio tissue diagnostics work flow automation coagulation monitoring sectors professional diagnostics core basis marketing distribution costs percentage sales compared roche group financial review roche finance report diagnostics division research development change mchf mchf cer research development core basis global restructuring operational excellence amortisation intangible assets impairment intangible assets total ifrs basis research development core costs increased driven development newgen instrument new personalised healthcare oncology tests molecular diagnostics micropump diabetes care digital pathology products tissue diagnostics investments new immunoassays laboratory coagulation portfolio professional diagnostics percentage sales core research development costs increased operational excellence expenses million swiss francs mainly due employeerelated costs graz austria diagnostics division general administration change mchf mchf cer administration restructuring expenses gains losses disposal property plant equipment general items general administration core basis global restructuring operational excellence alliances business combinations legal environmental settlements total ifrs basis general administration costs decreased mainly due costs transfer logistics centre within brazil operational excellence costs million swiss francs consisting mainly reorganisation expenses financial position diagnostics division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventories payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given roche finance report roche group financial reviewcurrency translation effects balance sheet amounts first half swiss franc strengthened many currencies following intervention swiss central bank trend reversed second half result end us dollar exchange rate start year euro slightly weaker swiss franc japanese yen strengthened swiss franc yearonyear swiss franc strengthened currencies brazilian real turkish lira overall effects largely netted total net operating assets diagnostics division consolidated swiss francs net working capital increase constant currencies driven increases receivables inventories main factors behind increases buildups trade receivable certain southern european countries increased inventory levels due product launches like cobas inventory increases related acquisitions buildup hitachisourced analysers earthquake japan receivables decreased million swiss francs following settlement public sector trade receivables government bonds greece payables also higher due accelerated efforts increase harmonise supplier payment terms longterm net operating assets total balance constant currencies increased investments property plant equipment notably instrument placements customers partially offset decreases intangible assets increased provisions mainly operational excellence employeerelated costs free cash flow diagnostics division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments increase decrease net working capital receivables inventories payables total increase decrease net working capital investments property plant equipment investments intangible assets total investments operating free cash flow sales detailed breakdown provided operating free cash flow diagnostics division decreased constant currencies upon translation swiss francs compared increase operating profit offset increases net working capital arose increases trade receivables overall higher inventory levels partly offset higher payables increases trade receivables due longer settlement times particularly southern europe reduced factoring activities higher inventory levels resulted launch growth key products professional diagnostics tissue diagnostics higher stock products sourced japan payables higher due accelerated efforts increase harmonise supplier payment terms overall negative effect operating free cash flow margin percentage points roche group financial review roche finance report corporate operating results corporate operating results summary change mchf mchf cer administration gains losses divestment subsidiaries restructuring expenses general items general administration costs core basis global restructuring legal environmental settlements total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results core eps general administration costs increased constant currencies due higher administration expenses constant currencies result shift certain finance functions pharmaceuticals division corporate total costs ifrs basis grew constant currencies million swiss francs million swiss francs higher rate core costs operational excellence restructuring expenses million swiss francs higher compared last years expenses corporate operating free cash flow showed increase net outflow driven higher allocated administration expenses due continuous changes organisational structure roche finance report roche group financial reviewforeign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer swiss francs change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy average rates euro us dollar major currencies lower swiss franc compared sales developments resulted negative impact percentage points translating growth constant currencies decline swiss franc terms core operating profit negative impact even higher percentage points due different currency structure operating costs sales core operating profit growth constant currencies translates decline currency translation exposure operating profit mitigated group majority cost base located outside switzerland sensitivity group sales core operating profit absolute terms movement foreign currencies swiss franc shown table currency sensitivities impact rise average exchange rate sales core operating profit versus swiss franc mchf mchf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany obviously large majority chugais costs denominated japanese yen roche group financial review roche finance report treasury taxation results treasury taxation results change change mchf mchf chf cer ifrs results operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position treasury taxation net debt pensions income taxes financial longterm assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury taxation treasury activities taxes paid dividends paid total see pages definition core results core eps roche finance report roche group financial reviewfinancial income financial income million swiss francs increase constant exchange rates swiss francs interest income income debt securities million swiss francs remained low levels due low prevailing interest rates net foreign exchange result gain million swiss francs compared loss million swiss francs improvement due foreign exchange gains million swiss francs venezuela following enactment law allowing group benefit predevaluation treatment certain transactions contrasts group incurred losses million swiss francs caused currency devaluation venezuela net income equity securities million swiss francs million swiss francs expected returns pension plan assets million swiss francs cer mostly due overall lower assumptions expected returns full analysis financial income given note consolidated financial statements financing costs financing costs million swiss francs decrease million swiss francs constant exchange rates swiss francs main driver decrease interest expenses million swiss francs decrease constant currencies reflects continued repayment debt incurred finance genentech transaction translation effect stronger swiss franc financing costs also include million swiss francs early redemption debt compared million swiss francs described note consolidated financial statements interest cost pension plans million swiss francs decrease cer mostly due lower discount rates full analysis financing costs given note consolidated financial statements income taxes groups effective core tax rate decreased percentage points decrease due mainly relatively lower percentage profit contribution higher tax jurisdictions notably japan decrease statutory tax rate basel switzerland addition drivers mentioned ifrs effective tax rate decreased due increased tax benefits equity compensation plans compared full details groups income tax positions given note consolidated financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf groups effective tax rate core basis global restructuring intangible assets groups effective tax rate ifrs basis roche group financial review roche finance report financial position decrease net debt mainly due positive free cash flow generation fully described net debt section increase net pension liability reflects falling interest rates leading discounted defined benefit obligation higher details given pensions section net tax liability decreased mainly due deferred tax benefit increased net pension liabilities recognised equity well fact taxes paid exceeded total income tax expense net derivative position decreased billion swiss francs mainly due lower valuations crosscurrency swaps following stronger us dollar compared euro interest payable relates mostly bonds notes coupon payment dates march decline due debt repayments december group held financial longterm assets market value billion swiss francs compared consist mostly holdings biotechnology companies acquired context licensing transactions scientific collaborations free cash flow cash outflow treasury activities increased slightly billion swiss francs mostly due higher foreign exchange losses lower gains marketable securities partially offset lower interest payments total taxes paid billion swiss francs increase constant exchange rates due prepayments tax settlement certain outstanding tax positions partly offset lower tax payments chugai total dividends paid billion swiss francs increase billion swiss francs compared reflecting increase roche group dividend net debt net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt period december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period roche finance report roche group financial reviewnet debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollar denominated debt includes bonds notes denominated euros swiss francs pounds sterling swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes net debt position group end billion swiss francs decrease billion swiss francs billion swiss francs start year mainly due free cash flow billion swiss francs described outflow billion swiss francs came transactions equity instruments executed cover exposure equity compensation plans issued employees addition billion swiss francs paid business combinations year group received billion swiss francs hedging collateral agreements set following financing genentech transaction previously described annual financial statements issuing debt finance genentech transaction group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar total exposure hedged issuance bonds notes approximately billion swiss francs see note collateral agreements entered derivative counterparties mitigate counterparty risk cash collateral billion swiss francs delivered roche increased cash collateral balance favour roche billion swiss francs start year billion swiss francs december collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also swiss franc pound sterling currently collateral balance moves approximately million us dollars foreign exchange rates move simultaneously collateral volatility decrease less million dollars movement foreign exchange rates mid nonus dollardenominated bonds notes repaid realised gain derivatives billion swiss francs relates mainly hedges nonus dollardenominated bonds notes various debt repayments billion swiss francs largely absorbed free cash flow billion swiss francs however significant impact net debt position full details groups marketable securities cash debt positions given notes consolidated financial statements roche group financial review roche finance report pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising funding asset management groups various defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources funding status balance sheet position mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability funding status overall funding status groups defined benefit plans decreased compared start year decrease came mainly increase defined benefit obligation arising fall discount rates comparison end plan assets broadly stable company contributions increasing million swiss francs compared million swiss francs group continues closely monitor funded status major pension funds addition cash injections group initiated plan changes several local pension plans example major pension funds removing early retirement incentives group continues introduce flexible retirement models better accommodate diverse needs ageing workforce expenses recorded income statement total pension expenses relating groups defined benefit plans million swiss francs compared million swiss francs increase primarily due lower curtailment gains million swiss francs compared million swiss francs addition million swiss francs past service costs million swiss francs past service income resulted mostly various oneoff plan amendments across group based revised actuarial assumptions end total pension expenses expected broadly stable compared full details groups pensions postemployment benefits given note consolidated financial statements roche finance report roche group financial reviewroche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group healthcare companies listed terms total shareholder return tsr ie share price growth plus dividends measured swiss francs actual exchange rates constant exchange rate roche also ranked number yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared weighted average return peer group actual constant exchange rates share prices healthcare outperformed many sectors despite continuing pressure healthcare prices sovereign debt issues europe usa good roche news flow rewarded relatively strong share price performance peer group abbott laboratories amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index roche group financial review roche finance report proposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security change chf chf chf basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements pages finance report payout ratio calculated dividend per share divided core earnings per share roche bonds notes finance genentech transaction group issued bonds notes equivalent billion swiss francs february march year debt raised early already repaid december includes early redemption billion us dollars notes originally due march march repurchase million euros notes originally due march june following tender offer repurchase million swiss francs notes originally due march november following tender offer repurchase million pounds sterling notes originally due march december following tender offer repurchase million pounds sterling notes originally due august december following tender offer maturity schedule groups bonds notes outstanding december shown table includes instruments already issue prior genentech transaction roche finance report roche group financial reviewbonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc principal principal principal principal total total musd meur mgbp mchf musd mchf beyond total total translated december exchange rates proceeds bonds notes swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated ongoing business free cash flow billion swiss francs includes cash generated operations well payment interest tax dividends second half free cash flow inflow billion swiss francs first half free cash flow outflow billion swiss francs included billion swiss francs used payment annual dividend described commentary net debt position group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk shortterm financing requirements group commercial paper programme united states issue billion us dollars unsecured commercial paper notes committed credit line billion euros available backstop line commercial paper notes totalling billion us dollars outstanding december longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors moodys upgraded september facilitate efficient access international capital markets credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable roche group financial review roche finance report financial risks december group net debt position billion swiss francs december billion swiss francs financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities mchf total mchf total cash cash equivalents money market instruments bonds debentures investments shares total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups billion swiss francs fixed income marketable securities remained strong invested aaaa range noted previously group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables billion swiss francs since beginning increasing financial difficulties certain southern european countries including spain italy portugal greece group leading supplier countries trade receivables billion swiss francs public customers countries group uses different measures improve collections countries including intense communication customers negotiations payment plans charging interest late payments legal action group also applying delivery cash public hospitals greece second half group accepted offer made greek government settle billion euros trade receivables zero coupon government bonds redeemable group sold vast majority bonds remaining bonds carrying value million swiss francs accounts receivables scope bond settlement already provided december reflect bond settlement terms become available settlement terms implied discount million euros average discount included results total financial result trade receivables zero coupon bonds scope settlement expense million swiss francs includes interest income gains losses sale bonds impairments remaining positions market value december liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years despite total debt billion swiss francs december roche enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling billion swiss francs december billion swiss francs billion swiss francs serve backstop line commercial paper programme december debt drawn credit lines roche finance report roche group financial reviewmarket risks market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices var data table indicates economic loss level period one month probability exceeded actual future economic gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchanges rates equity investment prices particularly periods high market volatilities furthermore var numbers include credit risk component market risk financial instruments december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total interest rate var decreased reflecting ageing debt repayment debt issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var increased slightly due lower diversification effects price risk arises mainly movements prices equity securities remained largely stable december group held equity securities market value billion swiss francs december billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations information financial risk management financial risks var methodology included note consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented various amendments existing standards interpretations material impact groups overall results financial position various new standards issued described note consolidated financial statements implemented latest except noted based initial analysis date group anticipate material impact groups overall results financial position amongst matters revised version ias employee benefits includes following changes existing standard eliminating option defer recognition actuarial gains losses defined benefit postemployment plans known corridor method group currently apply option rather uses option recognise gains losses directly equity option currently applied group henceforth requirement revised standard therefore change impact groups financial statements current method including expected income plan assets estimated asset return would replaced using discount rate used discount defined benefit obligation based initial review group estimates method applied consolidated financial statements net financial income would approximately million swiss francs lower published operating profit would materially affected roche group financial review roche finance report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statements roche finance report roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets associates financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche group roche group consolidated financial statements roche finance report roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital payments made defined benefit postemployment plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity instruments financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group roche group consolidated financial statementsroche group consolidated statement changes equity millions chf reserves non share retained fair controlling total capital earnings value hedging translation total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests movements december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests december roche group roche group consolidated financial statements roche finance report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders march preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results comparative period opening balances period restated new accounting policy always applied cases transitional requirements particular standard interpretation specify changes applied prospectively prospective application requires new accounting policy applied results current period comparative period restated addition comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights currently exercisable potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control roche finance report roche group notes roche group consolidated financial statementsinvestments associates accounted using equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights currently exercisable potential voting rights company balances transactions associates result unrealised income eliminated extent groups interest associate interests joint ventures reported using linebyline proportionate consolidation method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include cec global group functions communications human resources finance including treasury taxes pension fund management also included corporate legal corporate safety environmental services subdivisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income disposal foreign entity identified cumulative currency translation differences within comprehensive income relating foreign entity recognised income part gain loss divestment roche group notes roche group consolidated financial statements roche finance report revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research costs costs incurred purpose gaining new scientific technical knowledge understanding costs expensed incurred internal development costs costs incurred application research findings knowledge plan develop new products commercial production costs would qualify capitalisation intangible assets following criteria demonstrated technical feasibility completing development project successfully available use sale intention complete development project ability use sell results development project development project would generate economic benefits would normally evidenced existence size market results project products would result project availability adequate technical financial resources complete development project ability measure development expenditure reliably would qualify capitalisation intangible asset development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation met prior obtaining marketing approval regulatory authorities major markets internal development costs meet criteria therefore expensed incurred postmarketing studies regulatory approval phase iv costs pharmaceuticals business expensed incurred generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons safety surveillance designed detect rare longterm adverse effects much larger patient population longer time period possible earlier stages development costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured roche finance report roche group notes roche group consolidated financial statementsin addition internal research development activities group also party inlicensing similar arrangements alliance partners group may also acquire inprocess research development assets either business combinations purchases specific assets inprocess research development resources acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy reviewed impairment set impairment property plant equipment intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs available use intangible assets amortised straightline basis period expected benefit reviewed impairment reporting date research development embedded contracts strategic alliances group carefully assess whether upfront milestone payments constitute funding research development work acquisition asset licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth long term expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly comprehensive income pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly comprehensive income roche group notes roche group consolidated financial statements roche finance report equity compensation plans certain employees group participate equity compensation plans including separate plans genentech prior genentech transaction chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity cash settled plans liability recorded measured fair value reporting date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercise vested awards recorded reduction liability property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor primarily occurs diagnostics division assets subject finance leases initially reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases subsequently recognised earned income term lease based effective interest rate method lease income operating leases recognised lease term straightline basis roche finance report roche group notes roche group consolidated financial statementsbusiness combinations goodwill business combinations accounted using acquisition method accounting consideration transferred business combination measured fair value date acquisition consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group fair value consideration transferred also includes contingent consideration arrangements fair value directly attributable acquisitionrelated costs expensed current period reported within general administration expenses date acquisition group recognises identifiable assets acquired liabilities assumed noncontrolling interest acquired business identifiable assets acquired liabilities assumed initially recognised fair value group acquire ownership acquired business noncontrolling interests recorded proportion fair value acquired net assets attributable noncontrolling interest goodwill recorded surplus consideration transferred groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabilities acquired business functional currency business initial accounting business combination incomplete end reporting period provisional amounts used measurement period provisional amounts retrospectively adjusted additional assets liabilities may recognised reflect new information obtained facts circumstances existed acquisition date would affected measurement amounts recognised date known measurement period exceed twelve months date acquisition goodwill amortised assessed possible impairment reporting date additionally tested annually impairment goodwill may also arise upon investments associates surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associates changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy roche group notes roche group consolidated financial statements roche finance report impairment goodwill goodwill assessed possible impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss methodology used impairment testing described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying value estimated recoverable amount objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised consolidated income statement within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used statement cash flows provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available fair value hierarchy valuation techniques incorporate observable market data market conditions factors likely affect fair value financial instrument valuation techniques typically used derivative financial instruments fair values financial assets liabilities reporting date materially different reported carrying values unless specifically mentioned notes consolidated financial statements information fair value hierarchy included note risk management roche finance report roche group notes roche group consolidated financial statementsfinancial assets financial assets principally investments including marketable securities classified either fairvaluethroughprofit orloss availableforsale heldtomaturity loans receivables fairvaluethroughprofitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethrough profitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets fairvaluethrough profitorloss exclude transaction costs purchases sales recognised settlement date fairvalue throughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded comprehensive income except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised comprehensive income included financial income current period loans receivables subsequently carried amortised cost using effective interest rate method financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity securities market value original cost net previous impairment considered impaired availableforsale equity securities market value original cost net previous impairment sustained sixmonth period also considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded comprehensive income objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost net previous impairment fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred interest transferred financial assets created retained group recognised separate asset liability derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments discussed hedge accounting policy changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried amortised cost roche group notes roche group consolidated financial statements roche finance report hedge accounting purposes hedge accounting hedging relationships may three types fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence cash flow hedges hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included comprehensive income remaining ineffective portion reported financial income hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included comprehensive income remaining ineffective portion recorded financial income hedging instrument derivative comprehensive income cases entity disposed cumulative changes fair value hedging instrument recorded comprehensive income reclassified income debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method group derecognises financial liability contractual obligations discharged cancelled expired taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future roche finance report roche group notes roche group consolidated financial statementsdeferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates discontinued businesses noncurrent assetsheldforsale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria classified heldforsale earlier disposal group group assets disposed group single transaction together liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified heldforsale value recovered principally sale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification heldforsale measurement assets liabilities disposal group updated accordance applicable accounting policies initial classification held sale disposal groups recognised lower carrying value fair value less costs sell impairment losses initial classification heldforsale included income statement equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet potential obligations employees may arise respect certain groups equity compensation plans management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement consolidation subsidiaries associates group periodically undertakes transactions may involve obtaining right control significantly influence operations companies transactions include acquisition part equity companies purchase certain assets assumption certain liabilities contingent liabilities companies entering alliance agreements companies also included transactions involving special purpose entities similar vehicles cases management makes assessment whether group right control significantly influence companys operations based assessment company consolidated subsidiary associated company making assessment management considers underlying economic substance transaction contractual terms roche group notes roche group consolidated financial statements roche finance report business combinations group acquires control another business consideration transferred allocated identifiable assets acquired liabilities assumed noncontrolling interest acquired business residual recorded goodwill process involves management making assessment fair value items management judgement particularly involved recognition measurement following items intellectual property may include patents licences trademarks similar rights currently marketed products also rights scientific knowledge associated projects currently research development phases contingencies legal environmental matters contingent consideration arrangements recoverability accumulated tax losses previously incurred acquired company cases management makes assessment based underlying economic substance items concerned contractual terms order fairly present items leases group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months described revenue recognition may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries sales allowances group provisions accruals expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience management believes total provisions accruals items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet future periods consequently level sales recognised income statement future periods roche finance report roche group notes roche group consolidated financial statementsallowances doubtful accounts receivable group provisions accruals doubtful receivables december total million swiss francs see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account economic conditions management believes total provisions accruals items adequate based upon currently available information provisions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet future periods consequently marketing distribution expenses recognised income statement future periods property plant equipment intangible assets including goodwill group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment changes discount rates used could also lead impairments pensions postemployment benefits many groups employees participate postemployment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group companies party various legal proceedings including claims arising trade significant matters described note legal provisions december total million swiss francs management believes total provisions legal proceedings adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage problematic materials attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised balance sheet future periods roche group notes roche group consolidated financial statements roche finance report income taxes december net liability current income taxes million swiss francs net asset deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies changes ifrs implemented group implemented various minor amendments existing standards interpretations material impact groups overall results financial position new revised standards following new standards issued international accounting standards board iasb implemented latest ifrs consolidated financial statements ifrs joint arrangements ifrs disclosure interests entities ifrs fair value measurement ias revised employee benefits addition revisions issued ifrs financial instruments implementation date standard deferred latest group currently assessing potential impacts new revised standards interpretations effective january beyond group early adopted except noted based analysis date group anticipate material impact groups overall results financial position amongst matters revised version ias employee benefits includes following changes existing standard eliminating option defer recognition actuarial gains losses defined benefit postemployment plans known corridor method group currently apply option rather uses option recognise gains losses directly comprehensive income option currently applied group henceforth requirement revised standard therefore change impact groups financial statements current method including expected income plan assets estimated asset return would replaced using discount rate used discount defined benefit obligation based initial review group estimates method applied consolidated financial statements net financial income would approximately million swiss francs lower published operating profit would materially affected roche finance report roche group notes roche group consolidated financial statements operating segment information divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets impairment net assetsheldforsale equity compensation plan expenses roche group notes roche group consolidated financial statements roche finance report pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results subdivisional profit elimination profit within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets impairment net assetsheldforsale equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group nonoperating assets liabilities consist primarily balances related treasury pensions taxation matters roche finance report roche group notes roche group consolidated financial statementsnet operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group notes roche group consolidated financial statements roche finance report supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december major customers us national wholesale distributor amerisourcebergen corp represented approximately billion swiss francs billion swiss francs groups revenues approximately revenues pharmaceuticals operating segment residual diagnostics segment group also reported substantial revenues us national wholesale distributors cardinal health inc mckesson corp total three customers represented approximately quarter groups revenues chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone results jgaap basis results chugai consolidated roche group accordance ifrs roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche roche finance report roche group notes roche group consolidated financial statementsunder rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items east japan earthquake march severe earthquake tsunami struck pacific coast tohoku japan consequences chugais operations japan limited impacts disaster carefully reviewed regarding operations manufacturing processes supply chain damage chugais utsunomiya manufacturing plant resulted operations temporarily halted production products plant fully resumed end august costs recorded damage caused earthquake mainly relate utsunomiya plant consisted impairments restoration costs buildings partially damaged facilities writeoffs intermediates finished products costs shutdown net amounts received insurance costs recorded shown chugais contract manufacturers also affected earthquake result product shipment control lasted end october chugais promotional activities japan affected events cancelled employee resources diverted ensure continued product supply information flow customers factors certain negative impact chugais sales second half global issues east japan earthquake costs millions chf cost sales marketing distribution general administration total matters details chugais equity compensation plans given note roche group notes roche group consolidated financial statements roche finance report financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity security derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities gains losses debt security derivatives net writedowns impairments longterm loans net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costs millions chf year ended december interest expense amortisation debt discount gains losses debt derivatives net gains losses redemption repurchase bonds notes net time cost provisions interest cost defined benefit plans total financing costs net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income roche finance report roche group notes roche group consolidated financial statements income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total income expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates average expected rate decreased compared main driver decrease comes japan relatively higher local tax rate average group rate groups taxable profits japan decreased resulted decrease percentage japan contributes overall mix groups profit lower profit japan mainly due direct indirect effects east japan earthquake chugais results discussed note significant local tax rate changes main operating areas group compared besides decrease statutory tax rate basel switzerland groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development manufacturing tax credits us state tax impacts differences groups effective tax rate main contributors decrease groups effective tax rate compared lower average expected tax rate discussed increased equity compensation plan tax benefits lower us state tax impacts items partially offset increase nondeductible expenses well lower research development tax credit impact nondeductible expenses increased mainly due newly introduced us branded pharmaceutical product fee impact equity compensation plans effective tax rate decrease increase mainly due increase price underlying equity changes us state tax legislation resulted lower us state tax rate compared income tax benefits recorded respect equity compensation plans varies according price underlying equity million swiss francs million swiss francs income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefits approximately million swiss francs million swiss francs would recorded roche group notes roche group consolidated financial statements roche finance report tax effects comprehensive income millions chf pretax tax aftertax pretax tax aftertax amount benefit amount amount benefit amount availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred income taxes assets liabilities net deferred income tax assets liabilities movements amounts recorded balance sheet current income taxes shown table current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid charged credited income statement current income taxes adjustments recognised current tax prior periods charged credited equity equity compensation plans transactions shareholders currency translation effects net current income tax asset liability december roche finance report roche group notes roche group consolidated financial statementsdeferred income tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable mchf tax rate mchf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred income tax liabilities established withholding tax taxes would payable unremitted earnings foreign subsidiaries amounts currently regarded permanently reinvested total unremitted earnings group billion swiss francs december billion swiss francs movements amounts recorded balance sheet deferred income taxes shown table deferred income taxes movements recognised net assets liabilities millions chf property plant equipment temporary intangible assets differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december roche group notes roche group consolidated financial statements roche finance report business combinations acquisitions pvt effective april group acquired controlling interest privately owned companies pvt probenverteiltechnik gmbh based waiblingen germany pvt lab systems llc based atlanta georgia united states jointly pvt pvt global market leader providing customised automation workflow solutions vitro diagnostic testing large commercial hospital laboratories pvt reported part diagnostics operating segment acquisition complements strengthens groups portfolio clinical diagnostics market purchase consideration pvt probenverteiltechnik gmbh million euros million euros paid cash million euros arose contingent consideration arrangement purchase consideration pvt lab systems llc million us dollars paid cash contingent payment arrangement based achievement performancerelated milestones may arise end range outcomes undiscounted million euros liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting closing balance sheet foreign exchange rates mtm laboratories effective august group acquired controlling interest privately owned mtm laboratories ag mtm laboratories based heidelberg germany mtm laboratories develops vitro diagnostics detection diagnosis cancer focus cervical cancer early detection mtm laboratories reported part diagnostics operating segment acquisition complements groups portfolio offering cervical cancer testing roche tissue diagnostics business total purchase consideration million euros million euros paid cash million euros arose contingent consideration arrangement contingent payment arrangement based achievement one milestone may arise range outcomes undiscounted zero million euros liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting closing balance sheet foreign exchange rates anadys pharmaceuticals effective november group acquired controlling interest anadys pharmaceuticals inc anadys publicly owned us company based san diego california prior acquisition anadys listed nasdaq symbol ands anadys develops oral small molecule therapeutics potential treatment hepatitis c virus hcv infection reported part roche pharmaceuticals operating segment acquisition augment groups hcv portfolio total purchase consideration million us dollars paid cash combined purchase consideration million swiss francs consisting million swiss francs cash million swiss francs contingent consideration arrangements allocated shown table acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use marketing intangibles inventories deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration roche finance report roche group notes roche group consolidated financial statementsgoodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs directly attributable transaction costs million swiss francs incurred acquisitions reported within general administration expenses current period part operating result roche pharmaceuticals diagnostics operating segment million swiss francs million swiss francs respectively acquisitions impact results millions chf revenues inventory amortisation external fair value intangible operating customers adjustment assets profit net income impact reported results anadys pharmaceuticals division pvt mtm laboratories diagnostics division group estimated impact results acquisition assumed effective january anadys pharmaceuticals division pvt mtm laboratories diagnostics division group figures exclude directlyattributable transaction costs referred addition exclude integration costs million swiss francs related acquisitions diagnostics division corresponding tax impacts also excluded acquisitions net cash outflow millions chf cash cash net cash consideration paid acquired company outflow acquisitions contingent consideration paid prior year acquisitions total future acquisitions december group announced entered agreement acquire controlling interest verum diagnostica gmbh verum purchase consideration million euros cash million euros contingent consideration arrangement based munich germany verum privately held company specialised coagulation diagnostics focus platelet function testing rapidly growing field coagulation market acquisition verum allow group gain market share coagulation segment thus strengthen leading position clinical diagnostic market transaction closed effective january verum reported part diagnostics operating segment initial accounting transaction complete date consolidated financial statements approved issue board directors january therefore various disclosures including fair value net assets acquired made roche group notes roche group consolidated financial statements roche finance report acquisitions marcadia effective december group acquired controlling interest marcadia biotech inc marcadia privately owned us company based carmel indiana marcadia biopharmaceutical company focused developing broad portfolio drug candidates treatment diabetes obesity marcadia reported part roche pharmaceuticals operating segment total purchase consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement payment arrangement based achievement two separate performance milestones may arise range outcomes undiscounted zero million us dollars liability million swiss francs recognised acquisition date based managements best estimate probability adjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting closing balance sheet foreign exchange rates accounting marcadia acquisition provisional end finalised first half adjustments made provisional acquisition accounting reported annual financial statements medingo effective may group acquired controlling interest medingo ltd medingo majority owned subsidiary elron group based israel medingo engaged development semidisposable insulin patch pump reported part diagnostics operating segment total purchase consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement payment arrangement based achievement four separate performance milestones may arise range outcomes undiscounted zero million us dollars liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting payments made closing balance sheet foreign exchange rates bioimagene effective september group acquired controlling interest bioimagene inc bioimagene privately owned us company based sunnyvale california bioimagene engaged digital pathology workflow analysis field reported part diagnostics operating segment total purchase consideration million us dollars cash minor business combinations diagnostics business total purchase consideration million swiss francs cash combined purchase consideration million swiss francs consisting million swiss francs cash million swiss francs contingent consideration arrangements allocated shown table acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use technology intangibles use inventories deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration roche finance report roche group notes roche group consolidated financial statementsgoodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs directly attributable transaction costs million swiss francs incurred acquisitions reported within general administration expenses current period part operating result roche pharmaceuticals diagnostics operating segment million swiss francs acquisitions net cash outflow millions chf cash cash net cash consideration paid acquired company outflow acquisitions total contingent consideration arrangements group party certain contingent consideration arrangements arising previous business combination arrangements provisions arrangements recorded part provisions see note set table provisions discounted time value money material provisions contingent consideration arrangements millions chf january additional provisions created unused amounts reversed utilised year unwinding discount business combinations pvt mtm laboratories marcadia medingo minor business combinations currency translation effects december expected outflow resources within one year one two years two three years three years total roche group notes roche group consolidated financial statements roche finance report global restructuring plans operational excellence november group announced details concerning operational excellence global restructuring plan plan aimed adapting cost structures increasingly challenging market environment achieving significant efficiency productivity gains planned measures enable sustained investment research product development thus strengthen groups longterm innovation capability effective june group completed sale site palo alto california third party consideration million swiss francs cash million swiss francs paid result gain million swiss francs recorded within general administration expenses closure transfer research development activities roche sites palo alto completed end subsidiary roche palo alto llc retains certain residual obligations divested group completed divestment certain subsidiaries part operational excellence programme effective august group completed sale manufacturing site boulder colorado consideration includes certain contingent consideration arrangements based future performance site june net assets sold boulder considered disposal group written fair value less costs sell result impairment charge million swiss francs charged general administration expenses first half million swiss francs relates property plant equipment majority residual inventories second half loss million swiss francs recognised disposal effective october group sold research development site madison wisconsin including selected research assets consideration included equity stake contingent consideration arrangements based future achievement specified research development project milestones second half group divested research site kulmbach germany small property philippines total consideration received subsidiary divestments million swiss francs consisted million swiss francs cash marketable securities fair value million swiss francs deferred cash consideration million swiss francs received total loss divestment subsidiaries million swiss francs included general administration expenses roche pharmaceuticals operating segment group announced divest chemical production facility florence south carolina given unfavourable market chemical production assets groups expected future capacity requirements small molecules group currently anticipates restructuring activities substantially completed end total cost expected order billion swiss francs includes billion swiss francs already incurred billion swiss francs incurred roche finance report roche group notes roche group consolidated financial statementsoperational excellence restructuring costs millions chf employeerelated costs termination costs pensions postemployment benefits employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs divestment products businesses impairment net assetsheldforsale gains losses divestment subsidiaries total costs divestment products businesses impairment intangible assets reorganisation expenses total classification operational excellence restructuring costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales roche pharmaceuticals diagnostics marketing distribution roche pharmaceuticals diagnostics research development roche pharmaceuticals diagnostics general administration roche pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche group notes roche group consolidated financial statements roche finance report genentech transaction restructuring integration july group announced offer purchase outstanding shares genentech following closing transaction genentechs south san francisco site would become headquarters groups combined pharmaceuticals operations united states july group also announced roches pharmaceuticals business us would close manufacturing operations site nutley new jersey commercial operations would moved genentech research site palo alto california would closed research activities transferred nutley genentech subsequent announcements initial restructuring activities started nutley palo alto sites genentech transaction completed effective march following pharmaceuticals division initiated detailed integration programme align genentech business rest roches pharmaceuticals business restructuring activities completed end genentech transaction restructuring integration costs millions chf employeerelated costs termination costs pensions postemployment benefits retention plans employee benefits employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment site closure costs total site closure costs reorganisation expenses total employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans termination costs operational excellence genentech transaction restructuring integration employee benefits employee remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employee remuneration roche finance report roche group notes roche group consolidated financial statementsother employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits charges employee benefits operating results included relevant expenditure line function expected return plan assets interest cost defined benefit plans included part financial income financing costs respectively see note pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups long term financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans purpose financial statements defined contribution plans defined contribution plans typically consist payments employees group funds administered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly comprehensive income recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly comprehensive income roche group notes roche group consolidated financial statements roche finance report defined benefit plans expenses millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement funding groups various defined benefit plans overseen corporate level qualified independent actuaries carry valuations regular basis major plans annually reporting date funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan amounts recognised balance sheet postemployment benefits predominantly noncurrent reported non current assets liabilities defined benefit plans funding status millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported defined benefit plans reimbursement rights postemployment benefit assets postemployment benefit liabilities net recognised asset liability roche finance report roche group notes roche group consolidated financial statementsfurther detailed information plan assets defined benefit obligation given defined benefit plans fair value plan assets reimbursement rights millions chf fair value reimburse fair value reimburse plan assets ment rights total plan assets ment rights total january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost divestment subsidiaries curtailments settlements december invested shares equity instruments bonds debentures debt instruments property assets total included within fair value plan assets none groups shares none groups shares thousand groups nonvoting equity securities fair value million swiss francs thousand groups nonvoting equity securities fair value million swiss francs also included debt instruments issued group fair value million swiss francs none assets consist mainly cash special bonds equity funds alternatives mortgages commodities insurance policies roche group notes roche group consolidated financial statements roche finance report defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost divestment subsidiaries curtailments settlements december funded plans unfunded plans actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates returns investments salary benefit levels inflation rates costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity mortality tables used major schemes germany heubeck tables g japan national census life table switzerland bvg generational tables pensioners bvg projected nonpensioners united kingdom nonpensioners snal table rated years male years female future improvements medium cohort underpin united kingdom pensioners snal table rated years future improvements medium cohort underpin united states rp projected rates employee turnover disability early retirement based historical behaviour within group companies roche finance report roche group notes roche group consolidated financial statementsfinancial assumptions based market expectations period obligations settled ranges assumptions used actuarial valuations significant plans countries stable currencies interest rates shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates used calculate discounted present value defined benefit obligation determined reference market yields highquality corporate bonds government bonds countries deep market corporate bonds currency term bonds consistent obligation discounted interest cost included income statement calculated multiplying discount rate defined benefit obligation defined benefit plans sensitivity discount rate millions chf current service cost interest cost defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes administration costs borne plan based longterm market expectations actual performance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent recent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference expected return actual return twelvemonth period actuarial gainloss recorded directly comprehensive income actual return plan assets gain million swiss francs gain million swiss francs expected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances roche group notes roche group consolidated financial statements roche finance report medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend rate millions chf current service cost interest cost defined benefit obligation funding summary fiveyear summary funding status groups defined benefit plans shown table defined benefit plans summary funding status millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation increase decrease funding status arising experience adjustments fair value plan assets defined benefit obligation increase decrease funding status arising changes actuarial assumptions fair value plan assets defined benefit obligation cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs includes estimated million swiss francs additional contributions benefits paid unfunded plans estimated approximately million swiss francs roche finance report roche group notes roche group consolidated financial statementsamounts recorded comprehensive income actuarial gains losses recognised statement comprehensive income losses million swiss francs losses million swiss francs pretax total amount december accumulated loss million swiss francs accumulated loss million swiss francs addition recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly comprehensive income adjustment decrease million swiss francs decrease million swiss francs employee stock options equity compensation plans group operates several equity compensation plans including separate plans chugai effective january group adopted ifrs sharebased payment amongst matters standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses share option plans roche option plan chugai stock acquisition rights total share option plans equity compensation plans bonus stock awards roche connect roche stocksettled stock appreciation rights roche restricted stock unit plan chugai retirement stock acquisition rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expenses equitysettled cashsettled roche group notes roche group consolidated financial statements roche finance report cash inflow outflow equity compensation plans millions chf equitysettled equity compensation plans roche option plan exercises chugai stock acquisition rights exercises roche connect costs total equitysettled equity compensation plans cash outflow transactions equity instruments total cash inflow outflow equitysettled equity compensation plans net transactions equity instruments cashsettled plans included part movements net working capital roche stock appreciation rights net cash outflow transactions equity instruments arises sales purchases nonvoting equity securities genussscheine derivative instruments thereon held groups potential conversion obligations may arise groups equitysettled equity compensation plans derivative instruments mainly consist call options exercisable time maturity see note roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan following integration genentech group also established restricted stock unit rsu plan first awards plan made september employees genentech ssars issued accordance roche ssar plan regulations january including amendments effective january addenda including roche ssar plans addendum united states september remuneration committee determines number nonvoting equity securities genussscheine available plan year regulations collectively provide million nonvoting equity securities genussscheine available issuance roche ssar plan tenyear period rsus issued accordance roche restricted stock unit plan regulations effective september million nonvoting equity securities genussscheine available issuance tenyear period details plans given relevant sections share option plans roche option plan awards plan give employees right purchase nonvoting equity securities genussscheine exercise price specified grant date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche finance report roche group notes roche group consolidated financial statementsroche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price rights nontradable equitysettled awards tenyear duration vest two years chugai stock acquisition rights movement number rights outstanding weighted average weighted average number exercise price number exercise price rights jpy rights jpy outstanding january granted forfeited exercised expired outstanding december exercisable roche group notes roche group consolidated financial statements roche finance report chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number years remaining exercise price number exercise price year grant outstanding contractual life jpy exercisable jpy awards total issues share options issues share options including methodology used calculate fair value main inputs valuation models described issues share option plans roche chugai stock option plan acquisition rights number options granted underlying equity roche nonvoting equity securities chugai shares blocks currency swiss francs japanese yen vesting period progressively years years contractual life years years weighted average fair value options issued option pricing model used binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor na expected exit rate volatility roche chugai options determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche finance report roche group notes roche group consolidated financial statementsexercise share options weighted average share price roche nonvoting equity securities genussscheine date exercise roche option plan options swiss francs share options chugai shares underlying equity exercised year equity compensation plans bonus stock awards bonus members corporate executive committee awarded form immediately vesting nonvoting equity securities genussscheine total awards issued total fair value million swiss francs fair value awards calculated basis market value roche nonvoting equity securities grant date roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities genussscheine administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary non voting equity securities directly market december administrator held million nonvoting equity securities million programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function roche stocksettled stock appreciation rights introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities genussscheine reflecting value appreciation market price nonvoting equity securities grant date exercise date rights nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing non voting equity securities derivatives thereon see note roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche group notes roche group consolidated financial statements roche finance report roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average fair value rights granted calculated using binomial model inputs model consistent used roche option plan awards given previously except expected volatility resulting weighted average fair value per right swiss francs giving total fair value million swiss francs charged vesting period three years roche restricted stock unit plan first time september group issued restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities genussscheine vest threeyear period weighted average fair value awards granted swiss francs calculated basis market value roche nonvoting equity securities date issue discounted take account awards would accrue dividends vesting period roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december exercisable chugai retirement stock acquisition rights first time chugai issued stock acquisition rights lieu retirement gratuities system directors abolished rights issued thirtyyear duration vest upon holders retirement director chugai right entitles holder purchase chugai shares exercise price japanese yen total fair value rights issued equivalent million swiss francs million swiss francs calculated using binomial model inputs consistent used chugai stock appreciation rights given previously roche finance report roche group notes roche group consolidated financial statementsroche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers programme established beginning currently operates annual threeyear cycles terms currently outstanding awards set table amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate valuation also takes account defined rank performance structure determines payout plan roche stock appreciation rights employees certain north american subsidiaries group received stock appreciation rights sars part compensation sars nontradable cashsettled awards could exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point exercise exceeds strike price grant price issuance following implementation roche longterm see group awarded cashsettled sars awards made since roche stock appreciation rights millions chf liability december intrinsic value vested rights december outstanding awards end roche group notes roche group consolidated financial statements roche finance report property plant equipment property plant equipment movements carrying value assets millions chf buildings machinery land construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals business combinations divestment subsidiaries transfers reclassification assetsheldforsale depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value roche finance report roche group notes roche group consolidated financial statementsimpairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment impairment charges million swiss francs million swiss francs reported part cost sales million swiss francs million swiss francs research development impairment charges reported within general administration million swiss francs income million swiss francs received insurance companies respect impairments property plant equipment none mostly respect damage arising east japan earthquake see note borrowing costs capitalised property plant equipment million swiss francs using rate leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method roche group notes roche group consolidated financial statements roche finance report finance leases future minimum lease payments noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs roche finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assets millions chf january business combinations divestment subsidiaries impairment charge currency translation effects december allocated following cashgenerating units pharmaceuticals division roche pharmaceuticals chugai total pharmaceuticals division diagnostics division diabetes care professional diagnostics molecular diagnostics applied science tissue diagnostics strategic goodwill held divisional level allocated business areas total diagnostics division accumulated impairment losses goodwill goodwill arising investments associates classified part investments associates see note goodwill impairment testing pharmaceuticals division divisions subdivisions cashgenerating units used testing goodwill chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices chugai shares roche pharmaceuticals recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years valuations also include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data swiss capital markets including swiss federal government twentyyear bonds swiss market index weighted average tax rate used calculations corresponding pretax discount rate management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount roche group notes roche group consolidated financial statements roche finance report diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years estimates tissue diagnostics business area projected ten years management believes reflects longterm nature business valuations also include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data swiss capital markets including swiss federal government twentyyear bonds swiss market index weighted average tax rate used calculations corresponding pretax discount rate management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche group notes roche group consolidated financial statementsintangible assets movements carrying value assets continued millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total year ended december january business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use tanox acquisition roche pharmaceuticals years corangeboehringer mannheim acquisition diagnostics years ventana acquisition diagnostics years product intangibles available use intermune alliance roche pharmaceuticals na ventana acquisition diagnostics na classification amortisation impairment expenses millions chf amortisation impairment amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution diagnostics research development pharmaceuticals diagnostics total roche group notes roche group consolidated financial statements roche finance report internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives impairment intangible assets impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment roche pharmaceuticals operating segment recorded impairment charge million swiss francs diagnostics operating segment recorded impairment charge million swiss francs pharmaceuticals operating segment impairment charge million swiss francs recorded related decision stop development project acquired business combination outlicensed alliance partner asset concerned partly amortised written recoverable value million swiss francs based value use calculation using aftertax discount rate charge million swiss francs recorded resulting portfolio prioritisation decisions projects acquired separately part business combination assets concerned yet amortised fully written charges diagnostics operating segment impairment charge million swiss francs recorded mainly respect intangible assets use followed regular updating divisions business plans technology assessments second half assets concerned written recoverable amount million swiss francs based value use calculation using aftertax discount rate roche pharmaceuticals operating segment recorded impairment charge million swiss francs diagnostics operating segment recorded impairment charge million swiss francs amount recorded roche pharmaceuticals operating segment impairment charge million swiss francs recorded part operational excellence programme see note part programme division carried comprehensive portfolio review decided discontinue certain activities research early development addition certain product development activities discontinued transferred roche sites third parties result decisions intangible assets carrying value million swiss francs fully written apart operational excellence programme impairment charge million swiss francs also recorded pharmaceuticals division respect product intangibles available use follows primarily recent clinical data portfolio prioritisation decisions relating certain projects either alliance partners acquired business combinations assets concerned yet amortised fully written charges charge million swiss francs recorded resulting portfolio prioritisation decision project acquired part previous business combination asset concerned yet amortised written recoverable value million swiss francs based value use calculation using aftertax discount rate reversal previously recorded impairment loss million swiss francs recorded followed latest clinical data assessment project concerned diagnostics operating segment impairment charge million swiss francs recorded respect intangible assets use followed regular updating divisions business plans technology assessments second half assets concerned written recoverable amount million swiss francs based value use calculation using aftertax discount rate roche finance report roche group notes roche group consolidated financial statementsintangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december carrying value assets pharmaceuticals division million swiss francs amount approximately represents projects potential decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project question result commercialised product potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures undiscounted risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total associates groups investments associates accounted using equity method goodwill arising investments associates classified part investments associates investments associates millions chf share net income carrying value total investments associates group significant investments associates material transactions group associates additional information associates given note roche group notes roche group consolidated financial statements roche finance report financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets longterm employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent availableforsale investments mainly equity investments primarily investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably carrying value equity investments held cost million swiss francs million swiss francs million swiss francs loans receivable comprise loans third parties term one year inventories inventories millions chf raw materials supplies work process intermediates finished goods less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs million swiss francs roche finance report roche group notes roche group consolidated financial statements accounts receivable accounts receivable millions chf trade accounts receivable notes receivable allowances doubtful accounts chargebacks allowances total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs billion swiss francs allowances doubtful accounts receivable movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december expenses relating bad debts expensed marketing distribution totalled million swiss francs million swiss francs significant concentrations within trade receivables counterparty credit risk described note second half group accepted offer made greek government settle billion euros trade receivables nominal value zero coupon government bonds redeemable settlement terms implied discount million euros average discount additional allowances doubtful accounts totalling million swiss francs made respect bonds delivered point carrying value trade receivables net accumulated allowances doubtful accounts reclassified availableforsale marketable securities allowances utilised respect totalled million swiss francs subsequently group sold vast majority bonds total financial result trade receivables zero coupon bonds scope settlement expense million swiss francs includes interest income gains losses sale bonds impairment remaining position market value december roche group notes roche group consolidated financial statements roche finance report current assets current assets millions chf accrued interest income derivative financial instruments restricted cash total financial current assets prepaid expenses total nonfinancial current assets total current assets derivative financial instrument assets primarily related hedges nonus dollardenominated bonds notes issued finance genentech transaction decline compared december mainly due strengthening us dollar compared euro marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss bonds debentures total financial assets fairvaluethroughprofitorloss heldtomaturity financial assets money market instruments time accounts three months total heldtomaturity financial assets availableforsale financial assets shares bonds debentures money market instruments time accounts three months investments total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs us dollars euros investments held strategic purposes classified noncurrent see note shares consist primarily readily saleable equity securities bonds debentures carrying values contracted maturity debt securities shown roche finance report roche group notes roche group consolidated financial statementsbonds debentures millions chf contracted maturity within one year one five years five years total bonds debentures money market instruments contracted mature within one year december cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents accounts payable accounts payable millions chf trade accounts payable taxes payable dividends payable accounts payable total accounts payable accrued current liabilities accrued liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities roche group notes roche group consolidated financial statements roche finance report derivative financial instruments group uses derivative financial instruments part risk management activities discussed note derivative financial instruments carried fair value methods used determining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks managed using derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described cash flow hedges group issued bonds notes finance genentech transaction see note bonds notes denominated euros sterling group entered crosscurrency swaps hedge foreign exchange interest rate risk cash flow hedges qualify hedge accounting december instruments designated qualify hedge accounting recorded assets fair value million swiss francs assets million swiss francs ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table decline expected cash flows due stronger swiss franc euro us dollar pound sterling roche finance report roche group notes roche group consolidated financial statementsexpected cash flows qualifying cash flow hedges millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity decline expected cash flows due stronger swiss franc euro us dollar pound sterling expected cash flows qualifying cash flow hedges impact profit loss millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments instruments designated qualified fair value hedges recorded balance sheet december assets fair value million swiss francs gain million swiss francs recorded interest rate swaps fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments similar transactions interest rate swaps expired july underlying bond redeemed loss million swiss francs recorded interest rate swaps fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group entered forward contracts designated qualify fair value hedges december instruments recorded liabilities fair value million swiss francs liabilities million swiss francs loss million swiss francs recorded forward contracts loss million swiss francs result forward contracts offset changes fair value hedged equity investments group uses derivatives designated qualifying hedge relationship manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options roche group notes roche group consolidated financial statements roche finance report provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations acquired companies contingent consideration currency translation effects december current portion noncurrent portion total provisions year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations acquired companies contingent consideration contingent consideration utilisation divestment subsidiaries currency translation effects december current portion noncurrent portion total provisions expected outflow resources within one year one two years two three years three years total provisions roche finance report roche group notes roche group consolidated financial statementslegal provisions legal provisions consist number separate legal matters including claims arising trade various group companies majority cash outflows matters expected occur within next one three years although dependent development various litigations significant provisions discounted time value money material environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict estimated timings cash outflows shown table significant provisions discounted time value money material restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain global basis shown table provisions discounted time value money material matters employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past performance shown table significant provisions discounted time value money material provisions provisions mostly relate sales returns various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table significant provisions discounted time value money material contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note pharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions united states elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders december hlr defending approximately actions involving approximately plaintiffs brought various federal state courts throughout united states personal injuries allegedly resulting use accutane actions allege ibd result accutane use june hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product united states roche group notes roche group consolidated financial statements roche finance report actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation united states district court middle district florida tampa division july district court granted summary judgment favour hlr lead federal ibd cases plaintiffs appealed august rulings affirmed united states court appeals eleventh circuit october district court granted summary judgment favour hlr next five federal ibd cases plaintiffs appealed november may rulings affirmed united states court appeals eleventh circuit multiple recently filed matters remain pending actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff six cases assessing total compensatory damages totalling million us dollars first verdict reversed appeal retrial resulted verdict favour plaintiff assessing total compensatory damages million us dollars hlr currently process posttrial briefing second verdict million us dollars reversed appeal new jersey supreme court accepted hlrs petition certification review decision superior court new jersey appellate division regarding trial remains pending hlr appealed third verdict involved three plaintiffs superior court new jersey appellate division remains pending one trial involving three plaintiffs tried superior court jury reached defence verdicts two cases awarded compensatory damages million us dollars third case cases posttrial briefing additional trial commenced november resulting mistrial jury could reach verdict next two trials involving two plaintiffs scheduled october jury circuit court escambia county florida returned verdict favour plaintiff assessing total compensatory damages million us dollars subsequently reduced million us dollars court company october district court appeal state florida reversed entered judgment hlr supreme court florida declined review plaintiffs appeal additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims cabilly patents october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk filed patent lawsuit genentech city hope us district court southern district florida lawsuit relates patent cabilly ii patent coowned genentech city hope lawsuit seeks declaratory judgment patent invalidity unenforceability regard cabilly ii patent patent noninfringement regard certain gsk product december genentech filed motion dismiss alternative transfer central district california gsk dismissed florida lawsuit entirety february filed related action day northern district california genentech filed motion transfer central district california answer counterclaim gsk march april genentechs motion transfer granted february court issued claim construction order construing certain terms used claims cabilly ii patent summary judgment motions due filed january additional lawsuits genentech gsk andor human genome sciences inc hgs involving cabilly ii patent related us patent cabilly iii patent pending us district court central district california proceedings cases stayed additional lawsuits include claims gsk andor hgs cabilly patents infringed invalid unenforceable genentech violated antitrust unfair competition laws laws outcome matters determined time roche finance report roche group notes roche group consolidated financial statementsrituxan arbitration sanofihoechst october genentech biogen idec inc filed complaint sanofiaventis deutschland gmbh sanofi sanofiaventis us llc sanofiaventis us inc northern district california seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patents declaratory judgment patents invalid also october sanofi filed suit genentech biogen idec eastern district texas lufkin division claiming rituxan least eight genentech products infringe patents sanofi brought claims preliminary permanent injunctions compensatory exemplary damages relief genentech challenged venue texas case opinion federal circuit court appeals texas california cases consolidated northern district california district court issued claim construction order june sanofi filed motion reconsideration denied genentech biogen idec filed motions summary judgment sanofi opposed court heard motions november march ruled matter law genentech biogen idec infringe asserted patent claims may sanofi filed notice appeal courts noninfringement ruling claim construction order appeal pending addition october hoechst gmbh filed icc international court arbitration paris request arbitration genentech relating terminated agreement one hoechsts predecessors genentech pertained patents related patents outside united states hoechst seeking payments royalties sales genentech products damages breach contract relief icc arbitration hearing held august september june arbitrator issued intermediate decision indicating rituxan covered terminated agreement ordering genentech produce certain rituxan sales information december october group expects arbitrator use information ascertain amount damages awarded hoechst group recorded expense million swiss francs net assumed reimbursement portion groups obligation copromotion partner us biogen idec recorded within cost sales back royalty expense corresponding increase accrued liabilities balance sheet amounts accrued represent managements best estimate compensatory damages including interest may awarded hoechst based financial terms terminated agreement final amount decision may vary amounts provided nature andor extent damages awarded hoechst differ groups estimate genentech successfully challenges arbitrators decision july genentech filed declaration appeal court appeal paris initiate legal proceedings challenging arbitrators decision arbitrator subsequently stated parties june decision decide operative part underlying issue liability respect rituxan light statement genentech pursue previously filed action challenge arbitrators decision without prejudicing ability bring challenge future genentech anticipates substantially completing briefing liability amount owed license agreement arbitrator find liability march hearing issues currently scheduled april may outcome matters determined time rituxan investigation october genentech received subpoena united states department justice requesting documents related promotion rituxan genentech cooperated governments associated investigation previously investigation civil criminal nature genentech informed august criminal prosecutor handled matter government declined prosecute genentech criminally connection investigation civil matter still ongoing counsel genentech continued discussions government representatives status investigation genentechs views matter including potential resolution october government notified genentech decided make civil claim genentech governments investigation initiated complaint filed seal us district court eastern district pennsylvania individual plaintiff complaint unsealed december became basis civil litigation plaintiff roche holdings inc genentech following settlement discussions plaintiff genentech government agreed settlement claims approximately million us dollars court entered order dismissing case november roche group notes roche group consolidated financial statements roche finance report average wholesale prices litigation hlr roche laboratories inc rli genentech along approximately brand generic pharmaceutical companies named defendants several legal actions united states relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending five actions filed following states alabama mississippi new jersey kansas louisiana genentech defending one action filed state kansas discovery currently pending cases hlr rli genentech intend vigorously defend matters outcome matters determined time brand name prescription drugs litigations hlr along various branded pharmaceutical companies named defendant several legal actions united states brought retail pharmacies relating discounting practices brand name prescription drugs bnpd bnpd litigations plaintiffs allege denied discounts certain prescription drugs offered mail order managed care entities denial claimed violation robinsonpatman act rpa rpa federal law prohibits unlawful price discrimination addition plaintiffs alleged defendants conspired refusal offer certain discounts conspiracy claims defendants previously settled rpa claims remaining litigated december hlr defending approximately bnpd actions brought various federal state courts throughout united states discovery currently pending cases hlr currently scheduled trial bnpd matters hlr intends vigorously defend outcome matters determined time intermune litigation may june august september genentech named defendant along intermune inc former chief executive officer w scott harkonen four separate classaction complaints filed us district court northern district california behalf plaintiffs allegedly paid part purchase price product licensed genentech connectics corporation subsequently assigned intermune genentech responded complaints motion dismiss matters granted april plaintiffs filed amended complaints including state law claims may genentech responded complaints another motion dismiss heard september court granted genentechs motion dismiss respect claims leave plaintiffs replead specific claims california unfair competition law plaintiffs filed amended class action complaint december naming genentech defendant claims unfair competition law false advertising law consumer remedies law consumer protection law unjust enrichment genentech sought dismissal amended complaint september court entered order granting genentechs motion dismiss claims prejudice plaintiffs filed appeal district courts ruling united states court appeals ninth circuit december court appeals affirmed district courts ruling respects university pennsylvania litigation may genentech filed patent lawsuit university pennsylvania us district court northern district california lawsuit relates united states patent seeks declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seeking unspecified damages based sales herceptin genentech filed answer august may court issued claim construction order construing certain terms used claims patent december university filed motion summary adjudication certain facts order dated january court set april hearing date motion trial currently set june outcome matter determined time roche finance report roche group notes roche group consolidated financial statementspdl litigation august pdl biopharma pdl filed complaint genentech nevada state court seeking judicial declaration concerning genentechs obligation pay royalties certain exus sales herceptin avastin xolair lucentis agreement parties september pdl filed first amended complaint asserting additional claims genentech including breach contract breach implied covenant good faith fair dealing pdl also asserted new claims roche novartis intentional interference contractual relations addition declaratory relief pdl seeking monetary damages including liquidated punitive damages november genentech roche filed motion dismiss failure state claim roche filed additional motion dismiss lack personal jurisdiction court denied motions july outcome matter determined time gsk litigation september gsk genentech filed patent lawsuits one another case gsk also roche holding ltd us district courts district delaware northern district california respectively lawsuits concern gsks us patent nos gsk asserted claims genentech roche alleging infringement patents certain therapeutic antibody products although complaint specifically refers herceptin lawsuit genentech seeking judicial declaration noninfringement certain genentech products delaware action november genentech filed motion dismiss failure state claim motion transfer case california roche filed motion dismiss lack personal jurisdiction joining genentechs motion event personal jurisdiction motion denied parties subsequently stipulated roches dismissal genentech remains party motion transfer case california remains pending california action december court entered order staying california action pending resolution delaware court genentechs motion transfer outcome matters determined time boniva litigation hlr various roche affiliates named defendants numerous legal actions united states canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw onj atypical femoral fractures december hlr defending approximately actions brought federal state courts throughout united states action brought court queens bench province saskatchewan canada personal injuries allegedly resulting use boniva cases early discovery stages litigation one case set trial december individual trial results depend variety factors including many unique particular case hlr named roche affiliates intend vigorously defend matters outcome matters determined time diagnostics legal cases marsh supermarkets litigation july marsh supermarkets inc marsh filed breach contract suit roche diagnostics operations inc rdo lawsuit relates termination sublease agreement building rdo extensive argument bench trial hamilton superior court judge awarded marsh damages amounting million us dollars accrued legal provision rdo intends appeal judgment outcome appeal determined time roche group notes roche group consolidated financial statements roche finance report noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities consist mainly accrued longterm employee benefits debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt gains losses redemption repurchase bonds notes net amortisation debt discount foreign currency transaction gains losses net currency translation effects december consisting bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt reported longterm debt shortterm debt total debt fair value bonds notes billion swiss francs billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt roche finance report roche group notes roche group consolidated financial statementsbonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollardenominated notes floating rate months libor notes due february principal billion us dollars na notes due february principal million us dollars na us dollardenominated notes fixed rate notes due march principal billion us dollars na notes due march principal billion us dollars outstanding billion us dollars isin usual usaq notes due march principal billion us dollars isin usuam usas na notes due march principal billion us dollars isin usuan usau na european medium term note programme floating rate months euribor notes due march principal billion euros european medium term note programme fixed rate notes due march principal billion euros outstanding billion euros isin xs notes due march principal billion pounds sterling outstanding billion pounds sterling isin xs notes due march principal billion euros isin xs notes due march principal billion euros isin xs notes due august principal million pounds sterling outstanding million pounds sterling isin xs na swiss franc bonds bonds due march principal billion swiss francs outstanding billion swiss francs isin ch bonds due march principal billion swiss francs isin ch na genentech senior notes senior notes due july principal million us dollars na senior notes due july principal billion us dollars isin usag na senior notes due july principal million us dollars isin usac na total roche group notes roche group consolidated financial statements roche finance report bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes group issue bonds notes redemption repurchase bonds notes redemption us dollardenominated notes due date february group redeemed notes principal million us dollars original issue amount plus accrued original issue discount oid effective interest rate notes months libor plus cash outflow million swiss francs gain loss recorded redemption partial early redemption us dollardenominated notes december group resolved exercise option call redemption portion us dollardenominated fixed rate notes due march group redeemed billion us dollars total principal amount billion us dollars notes march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest december group already revised carrying value notes take account changes amounts timings estimated cash flow increase carrying value million swiss francs recorded within financing costs additional loss million swiss francs incurred upon final settlement notes effective interest rate notes partial repurchase eurodenominated notes june group completed tender offer nominal amount million euros fixed rate notes due march total principal amount billion euros cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs addition group terminated currency swaps used hedge foreign currency risk eurodenominated notes created additional loss million swiss francs reflecting change fair value hedging derivatives due changes interest rates total loss repurchase million swiss francs recorded within financing costs see note effective interest rate notes repurchased roche finance report roche group notes roche group consolidated financial statementspartial repurchase swiss francdenominated bonds november group completed tender offer nominal amount million swiss francs fixed rate bonds due march total principal amount billion swiss francs cash outflow million swiss francs plus accrued interest loss repurchase bonds million swiss francs effective interest rate bonds repurchased partial repurchase pound sterlingdenominated notes december group completed tender offer nominal amount million pounds sterling fixed rate notes due march total principal amount billion pounds sterling cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs effective interest rate notes repurchased partial repurchase pound sterlingdenominated notes december group completed tender offer nominal amount million pounds sterling fixed rate notes due august total principal amount million pounds sterling cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs effective interest rate notes repurchased redemption repurchase bonds notes redemption us dollardenominated notes due date february group redeemed notes principal billion us dollars original issue amount plus accrued original issue discount oid effective interest rate notes months libor plus cash outflow million swiss francs gain loss recorded redemption redemption european medium term note programme notes due date march group redeemed notes principal billion euros original issue amount plus accrued original issue discount oid effective interest rate notes months euribor plus plus including hedging cash outflow million swiss francs gain loss recorded redemption redemption genentech senior notes due date july group redeemed notes principal million us dollars original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded redemption early redemption us dollardenominated notes june group resolved exercise option call redemption us dollardenominated fixed rate notes due march principal billion us dollars group redeemed notes september amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal effective interest rate notes redemption cash outflow million swiss francs plus accrued interest loss redemption million swiss francs recorded within financing costs see note cash outflows redemption repurchase bonds notes millions chf us dollardenominated notes european medium term note programme eurodenominated notes european medium term note programme pound sterlingdenominated notes swiss franc bonds genentech senior notes total cash outflows redemption repurchase bonds notes roche group notes roche group consolidated financial statements roche finance report collateral arrangements group entered various currency swaps certain nonus dollar debt instruments issued collateral agreements entered counterparties currency swaps mitigate counterparty risk total billion swiss francs cash collateral delivered group billion swiss francs delivered group collateral received recorded increase cash corresponding increase accrued liabilities carrying value accrued liabilities respect agreements december billion swiss francs december accrued liabilities billion swiss francs commercial paper roche holdings inc commercial paper program march roche holdings inc established commercial paper program issue billion us dollars unsecured commercial paper notes guaranteed roche holding ltd committed credit line billion euros available backstop line maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount million us dollars average interest rate outstanding amounts due various dates march movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi argentine pesos average interest rate average interest rate balance primarily denominated taiwanese dollars repayment dates two years million swiss francs million swiss francs due within one year roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests movements december amounts transferred income statement gains million swiss francs reported royalties operating income losses million swiss francs financial income roche group notes roche group consolidated financial statements roche finance report changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment noncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests december entire losses transferred income statement million swiss francs reported financial income group completed purchase noncontrolling interests genentech effective march based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statementsshare capital december authorised issued share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity securities swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security approved would result total distribution shareholders million swiss francs subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities december december millions millions nonvoting equity securities derivative instruments total equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number non voting equity securities market value millions maturity strike price chf chf billions nonvoting equity securities derivative instruments feb sep total roche group notes roche group consolidated financial statements roche finance report nonvoting equity securities derivative instruments held groups potential conversion obligations may arise roche option plan roche stocksettled stock appreciation rights roche restricted stock unit plan see note mainly consist call options exercisable time maturity group holds none shares reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares nonvoting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise employee stock option plans exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested chugai stock options would dilutive effect net income chugai positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures roche finance report roche group notes roche group consolidated financial statementsdiluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests roche group notes roche group consolidated financial statements roche finance report statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense associates financial income financing costs income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment intangible assets impairment property plant equipment impairment net assetsheldforsale operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans net income expense provisions bad debt expense inventory writedowns adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche finance report roche group notes roche group consolidated financial statementscash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity significant noncash transactions significant noncash transactions none risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management specifically described detail financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai roche group notes roche group consolidated financial statements roche finance report carrying value fair value financial assets millions chf carrying value asset class fvtpla available heldfor heldto loans line items notes forsale trading maturity receivables total fair value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts three months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts three months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss roche finance report roche group notes roche group consolidated financial statementsfollowing implementation amendments ifrs financial instruments disclosures published march group established fair value hierarchy reflects significance inputs used making fair value measurements fair value hierarchy includes following three levels level quoted prices active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts three months bonds debentures shares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts three months bonds debentures shares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total availableforsale investments exclude equity securities held cost million swiss francs million swiss francs carried fair value see note december level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments unquoted shares significant transfers level level vice versa roche group notes roche group consolidated financial statements roche finance report changes fair value level financial assets millions chf january impairment charges valuation gains losses taken equity gains losses recognised income statement sales currency translation difference december credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets trade receivables subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective management trade receivables sustain growth profitability group optimising asset utilisation whilst maintaining risks acceptable level except noted significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties additionally group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held loans receivables none december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing december groups combined trade accounts receivable public customers southern europe spain italy greece portugal equivalent billion swiss francs representing groups consolidated trade accounts receivables billion swiss francs representing trade receivables spain italy portugal increased receivables greece decreased mainly due settlement trade receivables zero coupon government bonds redeemable group uses different measures improve collections countries including intense communication customers negotiations payment plans charging interest late payments legal action roche finance report roche group notes roche group consolidated financial statementsthe nature geographic location counterparties trade receivables overdue shown table include overdue balances us national wholesalers southern europe public customers described trade receivables overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable securities subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions within fixed income marketable securities group holds billion swiss francs government securities switzerland counterparties rating aa better exception greece million swiss francs december greek government bonds allocated bbb range relate settlement overdue receivables rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivatives group signs netting collateral agreements isda international swaps derivatives association master agreement respective counterparties order mitigate counterparty risk derivative positions group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued groups us affiliate roche holdings inc currencies us dollar total exposure hedged issuance bonds notes approximately billion swiss francs see note group returned billion swiss francs due strengthening us dollar euro pound sterling total billion swiss francs cash collateral delivered group collateral agreements set cash acceptable collateral collateral received delivered december related derivative activities roche group notes roche group consolidated financial statements roche finance report overdue assets financial assets past due impaired total billion swiss francs billion swiss francs analysis overdue impaired financial assets class millions chf total amount overdue month months months months year year ended december loans receivables year ended december loans receivables december financial assets whose terms renegotiated none liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time group liquidity reported senior management monthly basis roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements addition group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs decline undiscounted financial liabilities shown table mainly due debt repayments interest paid contractual maturity analysis financial liabilities millions chf total months months months years years years years years year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities total debt table shows undiscounted cash flows whereas carrying value consolidated balance sheet reflects discounted cash flows roche finance report roche group notes roche group consolidated financial statementsmarket risk market risk arises changing market prices groups financial assets financial liabilities market risk may affect group financial result value group equity group uses valueatrisk var measure impact market risk financial instruments roche defined var limits manage market risk var data reported monthly basis indicate value range within given financial instrument fluctuate preset probability result movements market prices var statistical measure implicitly assumes value changes recent past indicative value changes future var figures represent actual expected losses possible worstcase losses stated period var figures calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate longer holding periods increase probability higher value changes lead increased var figures actual future gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchange rates equity investment prices particularly periods high market volatilities furthermore var numbers include effect changes credit spreads market risk financial instruments millions chf december december var interest rate component var foreign exchange component var price component diversification var total market risk december total var financial assets liabilities million swiss francs december million swiss francs interest rate var decreased million swiss francs reflecting ageing debt repayment debt issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var increased slightly due lower diversification effects price risk arises mainly movements prices equity securities remained largely stable december group held equity securities market value billion swiss francs december billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations foreign exchange risk group operates across world exposed movements foreign currencies affecting group financial result value groups equity foreign exchange risk arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates transaction exposures foreign currency denominated financial statements groups foreign subsidiaries may vary upon consolidation swiss francdenominated group financial statements translation exposures roche group notes roche group consolidated financial statements roche finance report objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group currently hedge translation exposures using financial instruments group monitors transaction exposures daily basis net foreign exchange result corresponding var parameters reported monthly basis group uses forward contracts foreign exchange options cross currency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity changes interest rates may cause variations interest income expense addition may affect market value certain financial assets liabilities hedging instruments primary objective groups interest rate management protect net interest result interest rate exposures corresponding var parameters reported monthly basis group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments equity price risk reported var figure monthly basis senior management impairment financial assets impairments loans receivables mainly due increase expected nonrecoverability trade receivables write downs debt securities million swiss francs relate greek government bonds received exchange trade receivables see also note impairment losses asset classes millions chf loans receivables availableforsale financial assets shares investments debt securities total impairment losses roche finance report roche group notes roche group consolidated financial statementscapital group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events group completed purchase noncontrolling interests genentech effective march consideration net tax effects approximately billion swiss francs based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacts groups net equity effect groups business dividend policy capital monitored basis capitalisation calculated debt plus equity including non controlling interests reported senior management part groups regular internal management reporting groups capitalisation shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined local management roche group notes roche group consolidated financial statements roche finance report related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal mr lukas duschmal march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition charitable foundation established pool members admitted pool pool consists ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel million swiss francs million swiss francs million swiss francs members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board directors excluding chairman totalled million swiss francs million swiss francs million swiss francs chairman board directors members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee dr hippe mr oday dr soriot included table full calendar year joined cec similarly members corporate executive committee retiring part way year dr hunziker included full calendar year left cec roche finance report roche group notes roche group consolidated financial statementsremuneration chairman board directors members corporate executive committee millions chf salaries including bonuses expenses bonusspecial stock awards social security costs pensions postemployment benefits equity compensation plans retirement awards employee benefits total purposes remuneration disclosures values equity compensation plans including bonus special stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included financial statements roche holding ltd basel pages disclosures values equity compensation plans including special stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration chairman board directors members corporate executive committee ifrs basis see table deduct bonusspecial stock awards ifrs basis equity compensation plans ifrs basis add back bonusspecial stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration chairman board directors members corporate executive committee swiss legal basis chairman board directors members corporate executive committee bonusspecial stock awards members corporate executive committee granted bonus stock awards lieu part cashsettled bonus financial year none special stock awards roche longterm members corporate executive committee granted stocksettled stock appreciation rights ssars roche option plan rop restricted stock unit rsu awards ssars rop rsu awards roche group notes roche group consolidated financial statements roche finance report roche connect contributions paid group respect chairman board directors members corporate executive committee totalled million swiss francs million swiss francs roche performance share plan members corporate executive committee targeted awards cycle awards cycle award result zero two nonvoting equity securities depending upon achievement performance targets transactions former members corporate executive committee pensions tax consulting services totalling million swiss francs paid group two former corporate executive committee members million swiss francs four former members postemployment benefit plans transactions group various postemployment defined benefit plans employees group described note subsidiaries associates divestment subsidiaries effective may group sold wholly owned subsidiary roche vitamins inc rvi third party addition disclosed note group completed sale following whollyowned subsidiaries connection operational excellence programme roche colorado corporation boulder colorado roche madison inc madison wisconsin roche kulmbach gmbh kulmbach germany lascona land company inc philippines total consideration received divestments million swiss francs consisted million swiss francs cash marketable securities fair value million swiss francs deferred cash consideration million swiss francs received total gain loss divestments shown table gain loss divestment subsidiaries millions chf consideration net assets disposed property plant equipment goodwill provisions cash net assets accumulated currency translation adjustments total net assets disposed transaction costs provisions accruals residual obligations retained roche group gain loss divestment reported global restructuring costs roche pharmaceuticals operating segment general administration costs corporate operating segment roche finance report roche group notes roche group consolidated financial statementslisted companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonlisted companies share capital equity interest country company city millions argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd roche group notes roche group consolidated financial statements roche finance report share capital equity interest country company city millions el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france roche diagnostics france sas meylan eur roche sas boulognebillancourt cedex eur ventana medical systems sa illkirch eur germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag heidelberg eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen eur swisslab gmbh berlin eur greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf roche finance report roche group notes roche group consolidated financial statementsshare capital equity interest country company city millions peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc taguig city php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ag burgdorf chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics ag rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche glycart ag schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united kingdom piramed limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp roche group notes roche group consolidated financial statements roche finance report share capital equity interest country company city millions united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc san diego usd bioveris corporation wilmington usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd marcadia biotech inc wilmington usd memory pharmaceuticals corp montvale usd roche carolina inc florence usd roche diagnostics corporation indianapolis usd roche diagnostics operations inc indianapolis usd roche holdings inc wilmington usd roche insulin delivery systems inc fishers usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc south san francisco usd spring bioscience corp fremont usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela productos roche sa caracas vef vietnam roche diagnostics vietnam co ltd ho chi minh city usd share capital less local currency units roche finance report roche group notes roche group consolidated financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages franz b humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial reporting roche finance report report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation fair presentation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation fair presentation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgement including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation fair presentation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche group report statutory auditor consolidated financial statements roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey franois rouiller basel january roche group report independent auditor internal control financial reporting roche finance report multiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche group multiyear overview supplementary information roche finance report sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationadditions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information roche finance report core results eps information groups basic diluted earnings per share information given note consolidated financial statements pages group expanded presentation core results previously core eps shown full income statement group operating results divisions shown ifrs core basis allows transparent assessment actual results underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring costs see note excluded amortisation impairment intangible assets see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environmental expenses see financial review excluded global issues outside healthcare sector beyond groups control excluded includes directly attributable costs earthquake occurred japan march see note items material onetime treasury items major debt restructurings settlement pension plans currently none would excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables avoid doublecounting amounts shown global restructuring exclude items operational excellence programme included adjustment columns impairment intangible assets totalling million swiss francs see note additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary informationcore results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ global ecp tax ifrs turing sation impairment nations mental issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ ecp tax ifrs turing sation impairment nations mental benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche group multiyear overview supplementary information roche finance report divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ global ifrs turing sation impairment nations mental issues core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ ifrs turing sation impairment nations mental core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore eps core net income chf millions core net income attributable roche shareholders increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share core earnings per share diluted chf roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment intangible assets impairment net assetsheldforsale total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct net cash flow equitysettled equity compensation plans utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions associates current income tax net assets deferred income tax net assets postemployment benefit net assets marketable securities cash cash equivalents debt net assets net working capital longterm net operating assets total net assets net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions associates current income tax net assets deferred income tax net assets postemployment benefit net assets marketable securities cash cash equivalents debt net assets net working capital longterm net operating assets total net assets roche group multiyear overview supplementary information roche finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased four roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january roche finance report roche group roche securitiesnumber shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number nonvoting equity securities genussscheine held yearend total issue data per share nonvoting equity security chf earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche group roche securities roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies r isk management e quity board executive remuneration contingent liabilities board executive shareholdings ignificant shareholders appropriation available earnings report statutory auditor financial statements financial statements income statement millions chf year ended december income income participations interest income loans group companies interest investment income guarantee fee income group companies income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year roche holding ltd basel financial statements roche finance report balance sheet millions chf december december noncurrent assets participations longterm loans longterm loans group companies total noncurrent assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche finance report roche holding ltd basel financial statementsnotes financial statements summary significant accounting policies basis preparation financial statements financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group consolidated financial statements valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates movement recognised amounts millions chf share general legal free special available total capital reserve reserve reserve earnings equity january net income dividends transfer free reserve december net income dividends december net income dividends december roche holding ltd basel notes financial statements roche finance report contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december billion swiss francs billion swiss francs primarily relate additional bonds notes issued group companies finance genentech transaction guaranteed company described note roche group consolidated financial statements pages significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalski hoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal mr lukas duschmal march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition charitable foundation established pool members admitted pool pool consists ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder group pooled voting rights holds shares corresponding shares issued b ms maja oeri formerly member pool holds shares representing voting rights independently pool december shares participation owned novartis ltd basel including affiliates thereof c information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group c figures december supplied novartis ltd basel risk management detailed disclosures regarding risk management required swiss law included roche group consolidated financial statements pages roche finance report roche holding ltd basel notes financial statements board executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf b gehrig hoffmann p baschera ji bell p brabeckletmathe p bulcke b wm burns ljr de vink c franz b w frey da julius ar levinson oeri w ruttenstorfer h teltschik pr voser b b weder di mauro total remuneration board directors annual general meeting march w frey w ruttenstorfer stand reelection annual general meeting march p brabeckletmathe h teltschik stand reelection b annual general meeting march p bulcke c franz pr voser elected new members board directors remuneration dr levinson includes payments consulting work board membership genentech totalling thousand swiss francs thousand swiss francs chairman board directors dr franz b humer received remuneration shown table remuneration chairman board directors thousands chf annual salary including bonuses expenses bonusspecial stock awards pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total roche holding ltd basel notes financial statements roche finance report corporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table groups ceo dr severin schwan member corporate executive committee highest total remuneration remuneration also disclosed new members corporate executive committee dr hippe mr oday dr soriot included full calendar year joined cec similarly members corporate executive committee retiring part way year dr hunziker included full calendar year left cec remuneration members corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary including bonuses expenses bonusspecial stock awards pensions postemployment benefits equity compensation plans retirement awards employee benefits total remuneration received social security costs total bonusspecial stock awards chairman board directors members corporate executive committee granted total special stock awards chairman board directors received awards members cec received total awards awards granted dr schwan fair value awards employee calculated based fair value nonvoting equity securities genussscheine grant date chf chf discounted take account period blocked years years awards bonus members corporate executive committee awarded form bonus stock awards members cec received total awards awards granted dr schwan fair value awards employee calculated based fair value nonvoting equity securities genussscheine grant date discounted take account period blocked years years employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee equity compensation plans chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions awards disclosed note consolidated financial statements fair values used consolidated financial statements represent cost company grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions purposes remuneration disclosures values calculated based fair value employee receives taking account preliminary assessment completed performance conditions roche finance report roche holding ltd basel notes financial statementsthe chairman board directors members corporate executive committee eligible participate roche connect programme enables employees make regular deductions salaries purchase nonvoting equity securities group contributes programme allows employees purchase nonvoting equity securities discount usually members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employee swiss francs calculated using blackscholes formula assuming holding maturity deducting average twoyear vesting period members corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form part employees remuneration three equal annual amounts threeyear cycle award result zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities genussscheine psp one nonvoting equity security genussschein per award psp one nonvoting equity security genussschein per award resulting allocations multiplied nonvoting equity security genussschein price december swiss francs give fair value remuneration received employee remuneration equity compensation plans thousands chf roche connect ssar awards psp awards employer ssar ssar psp psp psp psp total contributions number fair value number number number fair value fair value total cec f schwan employee benefits include tax advisory costs incidental benefits transactions former members corporate executive committee pensions tax consulting services totalling million swiss francs paid group two former corporate executive committee members million swiss francs four former members roche holding ltd basel notes financial statements roche finance report board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine fb humer b f b gehrig hoffmann c p baschera ji bell p bulcke na na wm burns b ljr de vink c franz na na w frey na na da julius e ar levinson oeri c w ruttenstorfer na na pr voser na na b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars roche performance share plan see c mr hoffmann dr oeri held ubs longshort certificates roche bearer shares ro versus roche nonvoting equity securities rog mr de vink held roche american depositary receipts adrs e close relatives dr julius held roche nonvoting equity securities genussscheine f dr humer held rogtpk trackerplus certificates zrcher kantonalbank underlying roche nonvoting equity securities rog roche finance report roche holding ltd basel notes financial statementscorporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b ayyoubi hippe na na e hunziker na na e ga keller c oday p soriot total equity compensation awards roche option plan ssars roche performance share plan see b close relatives dr schwan held roche nonvoting equity securities genussscheine c close relatives dr keller held roche shares roche nonvoting equity securities genussscheine dr hippe appointed corporate executive committee effective april e dr hunziker resigned corporate executive committee effective march december chairman board directors mr burns members corporate executive committee held stocksettled stock appreciation rights ssars shown table awards held dr humer current chairman board directors mr burns current member board directors issued previous capacities members corporate executive committee option entitles holder purchase one roche nonvoting equity security genussschein specified strike price terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report included business report part annual report pages ssars awards held december year issue total schwan ayyoubi hippe ga keller oday p soriot total cec fb humer wm burns total strike price chf b expiry date feb b feb feb jan feb feb dr soriots awards included awards strike price chf expire january b dr hippes awards strike price chf expire april roche holding ltd basel notes financial statements roche finance report december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report pages business report part annual report award result zero two non voting equity securities genussscheine depending upon achievement performance targets discretion board directors end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities genussscheine total target number awards outstanding cycles december shown table roche performance share plan awards held december psp psp schwan ayyoubi hippe ga keller oday p soriot total cec allocation date feb feb december chairman board directors mr burns members corporate executive committee time held total stocksettled stock appreciation rights roche option plan awards outstanding total awards granted roche performance share plan roche finance report roche holding ltd basel notes financial statementsappropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche holding ltd basel appropriation available earnings roche finance report report statutory auditor financial statements report statutory auditor financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying financial statements roche holding ltd comprise income statement balance sheet notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgement including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation roche finance report roche holding ltd basel report statutory auditor financial statementssreport legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche holding ltd basel report statutory auditor financial statements roche finance report published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identi fied words believes expects anticipates projects intends fax seeks estimates future similar expressions discussion among things strategy goals plans media office intentions various factors may cause actual results differ group communications materially future reflected forwardlooking basel switzerland statements contained annual report among others tel pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products market fluctuations currency exchange rates general investor relations financial market conditions uncertainties discovery basel switzerland development marketing new products new uses tel existing products including without limitation negative results fax clinical trials research projects unexpected side effects pipeline marketed products increased government world wide web pricing pressures interruptions production loss wwwrochecom inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coverage order publications tel statement regarding earnings per share growth profit fax forecast interpreted mean roches email baselwebmasterrochecom earnings earnings per share subsequent period necessarily match exceed historical published earnings next annual general meeting earnings per share roche march trademarks mentioned enjoy legal protection roche finance report published german english case doubt differences interpretation english version shall prevail german text printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationse roche finance report fhoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom